

Anthony E Lang

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7769391/anthony-e-lang-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

987
papers

88,631
citations

142
h-index

273
g-index

1,063
ext. papers

102,958
ext. citations

7.4
avg, IF

8.19
L-index

#	Paper	IF	Citations
987	Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. <i>Movement Disorders</i> , 2008 , 23, 2129-70	7	3156
986	Parkinson's disease. <i>Lancet, The</i> , 2015 , 386, 896-912	40	2652
985	MDS clinical diagnostic criteria for Parkinson's disease. <i>Movement Disorders</i> , 2015 , 30, 1591-601	7	2371
984	Parkinson disease. <i>Nature Reviews Disease Primers</i> , 2017 , 3, 17013	51.1	1700
983	Parkinson's disease. First of two parts. <i>New England Journal of Medicine</i> , 1998 , 339, 1044-53	59.2	1636
982	Levodopa and the progression of Parkinson's disease. <i>New England Journal of Medicine</i> , 2004 , 351, 2498-508	59.2	1355
981	Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. <i>New England Journal of Medicine</i> , 2009 , 361, 1651-61	59.2	1351
980	Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. <i>New England Journal of Medicine</i> , 2001 , 345, 956-63	59.2	1283
979	A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. <i>New England Journal of Medicine</i> , 2000 , 342, 1484-91	59.2	1253
978	Phenomenology and classification of dystonia: a consensus update. <i>Movement Disorders</i> , 2013 , 28, 863-73	7	1217
977	Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. <i>Lancet Neurology, The</i> , 2008 , 7, 583-90	24.1	1075
976	Consensus statement on the diagnosis of multiple system atrophy. <i>Journal of the Neurological Sciences</i> , 1999 , 163, 94-8	3.2	1006
975	Criteria for the diagnosis of corticobasal degeneration. <i>Neurology</i> , 2013 , 80, 496-503	6.5	1004
974	Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. <i>Archives of Neurology</i> , 2010 , 67, 589-95		988
973	Parkinson's disease. Second of two parts. <i>New England Journal of Medicine</i> , 1998 , 339, 1130-43	59.2	972
972	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. <i>Movement Disorders</i> , 2017 , 32, 853-864	7	840
971	Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. <i>Brain</i> , 2005 , 128, 2240-9	11.2	837

970	Frontal lobe dysfunction in Parkinson's disease. The cortical focus of neostriatal outflow. <i>Brain</i> , 1986 , 109 (Pt 5), 845-83	11.2	817
969	Pharmacological treatment of Parkinson disease: a review. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 311, 1670-83	27.4	816
968	Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. <i>Movement Disorders</i> , 2007 , 22, 41-7	7	802
967	Randomized controlled trial of intraputaminal glial cell line-derived neurotrophic factor infusion in Parkinson disease. <i>Annals of Neurology</i> , 2006 , 59, 459-66	9.4	785
966	A double-blind, delayed-start trial of rasagiline in Parkinson's disease. <i>New England Journal of Medicine</i> , 2009 , 361, 1268-78	59.2	694
965	Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. <i>Annals of Neurology</i> , 2003 , 54, 93-101	9.4	691
964	Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. <i>Neurology</i> , 2003 , 60, 69-73	6.5	674
963	Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. <i>Movement Disorders</i> , 2006 , 21 Suppl 14, S290-304	7	651
962	MDS research criteria for prodromal Parkinson's disease. <i>Movement Disorders</i> , 2015 , 30, 1600-11	7	645
961	The anatomical basis of symptomatic hemidystonia. <i>Brain</i> , 1985 , 108 (Pt 2), 463-83	11.2	589
960	Neurophysiological identification of the subthalamic nucleus in surgery for Parkinson's disease. <i>Annals of Neurology</i> , 1998 , 44, 622-8	9.4	580
959	Double-blind evaluation of subthalamic nucleus deep brain stimulation in advanced Parkinson's disease. <i>Neurology</i> , 1998 , 51, 850-5	6.5	547
958	Effect of GPi pallidotomy on motor function in Parkinson's disease. <i>Lancet, The</i> , 1995 , 346, 1383-7	40	547
957	Dependence of subthalamic nucleus oscillations on movement and dopamine in Parkinson's disease. <i>Brain</i> , 2002 , 125, 1196-209	11.2	545
956	Procedural learning and neostriatal dysfunction in man. <i>Brain</i> , 1988 , 111 (Pt 4), 941-59	11.2	477
955	A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. <i>Archives of Neurology</i> , 2002 , 59, 1937-43		470
954	High-frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor. <i>Annals of Neurology</i> , 1997 , 42, 292-9	9.4	451
953	Gastrointestinal dysfunction in Parkinson's disease. <i>Lancet Neurology, The</i> , 2015 , 14, 625-39	24.1	436

952	Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. <i>Brain</i> , 2009 , 132, 1376-85	11.2	432
951	Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. <i>Annals of Neurology</i> , 2003 , 54 Suppl 5, S15-9	9.4	423
950	Cortical-basal ganglionic degeneration. <i>Neurology</i> , 1990 , 40, 1203-12	6.5	422
949	Beta oscillatory activity in the subthalamic nucleus and its relation to dopaminergic response in Parkinson's disease. <i>Journal of Neurophysiology</i> , 2006 , 96, 3248-56	3.2	413
948	Neuropsychological consequences of chronic bilateral stimulation of the subthalamic nucleus in Parkinson's disease. <i>Brain</i> , 2000 , 123 (Pt 10), 2091-108	11.2	411
947	Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. <i>JAMA - Journal of the American Medical Association</i> , 2002 , 287, 455-63	27.4	408
946	Posteroventral medial pallidotomy in advanced Parkinson's disease. <i>New England Journal of Medicine</i> , 1997 , 337, 1036-42	59.2	392
945	A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. <i>Brain</i> , 2008 , 131, 2720-8	11.2	392
944	Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. <i>Neurology</i> , 1982 , 32, 1335-46	6.5	377
943	Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. <i>Movement Disorders</i> , 2017 , 32, 1264-1310	7	375
942	Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. <i>Neurology</i> , 2006 , 67, 1254-76.5		365
941	Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. <i>Neurology</i> , 2001 , 56, 1702-6	6.5	358
940	Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. <i>Archives of Neurology</i> , 2004 , 61, 1044-53		356
939	Globus pallidus internus pallidotomy for generalized dystonia. <i>Movement Disorders</i> , 1997 , 12, 865-70	7	329
938	Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. <i>Neurology</i> , 2006 , 66, 845-51	6.5	328
937	Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. <i>Movement Disorders</i> , 2010 , 25, 578-86	7	319
936	Globus pallidus deep brain stimulation for generalized dystonia: clinical and PET investigation. <i>Neurology</i> , 1999 , 53, 871-4	6.5	308
935	Technology in Parkinson's disease: Challenges and opportunities. <i>Movement Disorders</i> , 2016 , 31, 1272-82		305

934	Ten-year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation. <i>Archives of Neurology</i> , 2011 , 68, 1550-6		304
933	Impulse control disorders in Parkinson disease: a multicenter case--control study. <i>Annals of Neurology</i> , 2011 , 69, 986-96	9.4	296
932	Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. <i>Movement Disorders</i> , 2014 , 29, 454-62	7	290
931	Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. <i>Archives of Neurology</i> , 2007 , 64, 212-6		289
930	Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group. <i>Annals of Neurology</i> , 1996 , 39, 37-45	9.4	286
929	Definition and classification of hyperkinetic movements in childhood. <i>Movement Disorders</i> , 2010 , 25, 1538-49	7	275
928	Prospective prevalence of pathologic gambling and medication association in Parkinson disease. <i>Neurology</i> , 2006 , 66, 1750-2	6.5	273
927	Long-term hardware-related complications of deep brain stimulation. <i>Neurosurgery</i> , 2002 , 50, 1268-74; discussion 1274-6	3.2	272
926	Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. <i>Annals of Neurology</i> , 2010 , 68, 18-27	9.4	270
925	Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. <i>Neurology</i> , 2002 , 58, 11-7	6.5	270
924	Urate as a predictor of the rate of clinical decline in Parkinson disease. <i>Archives of Neurology</i> , 2009 , 66, 1460-8		265
923	Utility of an objective dyskinesia rating scale for Parkinson's disease: inter- and intrarater reliability assessment. <i>Movement Disorders</i> , 1994 , 9, 390-4	7	262
922	Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease. <i>Journal of Neurosurgery</i> , 2003 , 99, 489-95	3.2	257
921	Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. <i>Lancet Neurology</i> , 2004 , 3, 309-16	24.1	256
920	Current Concepts in Diagnosis and Treatment of Functional Neurological Disorders. <i>JAMA Neurology</i> , 2018 , 75, 1132-1141	17.2	252
919	Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. <i>Archives of Neurology</i> , 2008 , 65, 716-23		251
918	Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias. <i>Brain</i> , 2006 , 129, 1059-69	11.2	250
917	Consensus statement on the diagnosis of multiple system atrophy. American Autonomic Society and American Academy of Neurology. <i>Clinical Autonomic Research</i> , 1998 , 8, 359-62	4.3	248

916	Deciphering the role of heterozygous mutations in genes associated with parkinsonism. <i>Lancet Neurology, The</i> , 2007 , 6, 652-62	24.1	242
915	Long-term follow-up of unilateral pallidotomy in advanced Parkinson's disease. <i>New England Journal of Medicine</i> , 2000 , 342, 1708-14	59.2	239
914	Contemporary assessment and pharmacotherapy of Tourette syndrome. <i>NeuroRx</i> , 2006 , 3, 192-206		237
913	Effects of apomorphine on subthalamic nucleus and globus pallidus internus neurons in patients with Parkinson's disease. <i>Journal of Neurophysiology</i> , 2001 , 86, 249-60	3.2	236
912	Mutations in GNAL cause primary torsion dystonia. <i>Nature Genetics</i> , 2013 , 45, 88-92	36.3	229
911	Neuropsychological outcome of GPi pallidotomy and GPi or STN deep brain stimulation in Parkinson's disease. <i>Brain and Cognition</i> , 2000 , 42, 324-47	2.7	229
910	Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. <i>Annals of Neurology</i> , 2002 , 51, 604-12	9.4	227
909	Differential neuronal activity in segments of globus pallidus in Parkinson's disease patients. <i>NeuroReport</i> , 1994 , 5, 1533-7	1.7	226
908	Primary dystonia is more responsive than secondary dystonia to pallidal interventions: outcome after pallidotomy or pallidal deep brain stimulation. <i>Neurosurgery</i> , 2004 , 54, 613-19; discussion 619-21	3.2	224
907	Pallidal neuronal activity: implications for models of dystonia. <i>Annals of Neurology</i> , 2003 , 53, 480-8	9.4	223
906	Localization of clinically effective stimulating electrodes in the human subthalamic nucleus on magnetic resonance imaging. <i>Journal of Neurosurgery</i> , 2002 , 97, 1152-66	3.2	222
905	A comparison of the mini mental state exam to the Montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease. <i>Movement Disorders</i> , 2008 , 23, 297-9	7	221
904	Comparative effects of unilateral and bilateral subthalamic nucleus deep brain stimulation. <i>Neurology</i> , 1999 , 53, 561-6	6.5	220
903	Short and long latency afferent inhibition in Parkinson's disease. <i>Brain</i> , 2003 , 126, 1883-94	11.2	214
902	Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. <i>Lancet Neurology, The</i> , 2017 , 16, 552-563	24.1	209
901	αSynuclein oligomers and clinical implications for Parkinson disease. <i>Annals of Neurology</i> , 2013 , 73, 155-69.4		209
900	Deep brain stimulation: preoperative issues. <i>Movement Disorders</i> , 2006 , 21 Suppl 14, S171-96	7	208
899	Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. <i>Movement Disorders</i> , 2004 , 19, 656-62	7	208

898	How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorder. <i>Brain</i> , 2012 , 135, 1860-70	11.2	207
897	Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. <i>Movement Disorders</i> , 2006 , 21, 1941-6	7	207
896	Psychogenic movement disorders. <i>Current Opinion in Neurology</i> , 2009 , 22, 430-6	7.1	205
895	Interface between tauopathies and synucleinopathies: a tale of two proteins. <i>Annals of Neurology</i> , 2006 , 59, 449-58	9.4	204
894	Memory and learning in early Parkinson's disease: evidence for a "frontal lobe syndrome". <i>Brain and Cognition</i> , 1990 , 13, 211-32	2.7	204
893	Early-onset Parkinson's disease caused by a compound heterozygous DJ-1 mutation. <i>Annals of Neurology</i> , 2003 , 54, 271-4	9.4	202
892	Apraxia in movement disorders. <i>Brain</i> , 2005 , 128, 1480-97	11.2	201
891	Stimulation of the subthalamic nucleus and impulsivity: release your horses. <i>Annals of Neurology</i> , 2009 , 66, 817-24	9.4	199
890	Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. <i>Lancet Neurology</i> , 2014 , 13, 676-85	24.1	197
889	Caffeine for treatment of Parkinson disease: a randomized controlled trial. <i>Neurology</i> , 2012 , 79, 651-8	6.5	197
888	Long-term Hardware-related Complications of Deep Brain Stimulation. <i>Neurosurgery</i> , 2002 , 50, 1268-1276	6.2	196
887	Distribution, type, and origin of Parkin mutations: review and case studies. <i>Movement Disorders</i> , 2004 , 19, 1146-57	7	194
886	Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease. <i>JAMA Neurology</i> , 2015 , 72, 100-5	17.2	191
885	Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. <i>Annals of Neurology</i> , 2015 , 78, 248-57	9.4	190
884	Dementia as the most common presentation of cortical-basal ganglionic degeneration. <i>Neurology</i> , 1999 , 53, 1969-74	6.5	188
883	Long-term outcome of bilateral pallidal deep brain stimulation for primary cervical dystonia. <i>Neurology</i> , 2007 , 68, 457-9	6.5	187
882	Globus pallidus stimulation activates the cortical motor system during alleviation of parkinsonian symptoms. <i>Nature Medicine</i> , 1997 , 3, 671-4	50.5	184
881	Botulinum toxin for simple motor tics: a randomized, double-blind, controlled clinical trial. <i>Neurology</i> , 2001 , 56, 605-10	6.5	181

880	Bilateral globus pallidus stimulation for Huntington's disease. <i>Annals of Neurology</i> , 2004 , 56, 290-4	9.4	179
879	Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export. <i>Nature Genetics</i> , 2015 , 47, 579-81	36.3	176
878	Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations. <i>Movement Disorders</i> , 2018 , 33, 660-677	7	174
877	Effects of apomorphine on globus pallidus neurons in parkinsonian patients. <i>Annals of Neurology</i> , 1997 , 42, 767-75	9.4	174
876	Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. <i>Movement Disorders</i> , 2007 , 22, 2409-17	7	174
875	Long-term follow-up of thalamic deep brain stimulation for essential and parkinsonian tremor. <i>Neurology</i> , 2003 , 61, 1601-4	6.5	174
874	Hemiballism: revisiting a classic disorder. <i>Lancet Neurology, The</i> , 2003 , 2, 661-8	24.1	173
873	Drug-induced deactivation of inhibitory networks predicts pathological gambling in PD. <i>Neurology</i> , 2010 , 75, 1711-6	6.5	171
872	Cortical and spinal abnormalities in psychogenic dystonia. <i>Annals of Neurology</i> , 2006 , 59, 825-34	9.4	169
871	DJ-1 (PARK7) mutations are less frequent than Parkin (PARK2) mutations in early-onset Parkinson disease. <i>Neurology</i> , 2004 , 62, 389-94	6.5	169
870	Parkinsonian syndromes associated with hydrocephalus: case reports, a review of the literature, and pathophysiological hypotheses. <i>Movement Disorders</i> , 1994 , 9, 508-20	7	168
869	Striatal dopamine distribution in parkinsonian patients during life. <i>Journal of the Neurological Sciences</i> , 1985 , 69, 223-30	3.2	165
868	The gene for paroxysmal non-kinesigenic dyskinesia encodes an enzyme in a stress response pathway. <i>Human Molecular Genetics</i> , 2004 , 13, 3161-70	5.6	164
867	Chorein detection for the diagnosis of chorea-acanthocytosis. <i>Annals of Neurology</i> , 2004 , 56, 299-302	9.4	162
866	Identification and characterization of neurons with tremor-frequency activity in human globus pallidus. <i>Experimental Brain Research</i> , 1997 , 113, 557-63	2.3	160
865	Deep brain stimulation for Parkinson's disease dissociates mood and motor circuits: a functional MRI case study. <i>Movement Disorders</i> , 2003 , 18, 1508-16	7	160
864	A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. <i>Lancet Neurology, The</i> , 2011 , 10, 415-23	24.1	159
863	Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. <i>Movement Disorders</i> , 2002 , 17, 303-12	7	159

862	The prion hypothesis in Parkinson's disease: Braak to the future. <i>Acta Neuropathologica Communications</i> , 2013 , 1, 2	7.3	155
861	Practical guidelines for managing adults with 22q11.2 deletion syndrome. <i>Genetics in Medicine</i> , 2015 , 17, 599-609	8.1	154
860	Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's. <i>Annals of Neurology</i> , 2016 , 80, 674-685	9.4	154
859	Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. <i>Neurology</i> , 2013 , 80, 1698-701	6.5	152
858	Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists. <i>Archives of Neurology</i> , 2004 , 61, 97-102		152
857	Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results. <i>Movement Disorders</i> , 2015 , 30, 500-9	7	151
856	Nomenclature of genetic movement disorders: Recommendations of the international Parkinson and movement disorder society task force. <i>Movement Disorders</i> , 2016 , 31, 436-57	7	148
855	Teaching tape for the motor section of the Toronto Western Spasmodic Torticollis Scale. <i>Movement Disorders</i> , 1997 , 12, 570-5	7	147
854	Disease-modifying strategies for Parkinson's disease. <i>Movement Disorders</i> , 2015 , 30, 1442-50	7	146
853	Predicting motor decline and disability in Parkinson disease: a systematic review. <i>Archives of Neurology</i> , 2002 , 59, 1724-8		146
852	Randomized Delayed-Start Trial of Levodopa in Parkinson's Disease. <i>New England Journal of Medicine</i> , 2019 , 380, 315-324	59.2	145
851	Crossroads in GDNF therapy for Parkinson's disease. <i>Movement Disorders</i> , 2006 , 21, 136-41	7	145
850	LRRK2 gene in Parkinson disease: mutation analysis and case control association study. <i>Neurology</i> , 2005 , 65, 696-700	6.5	145
849	The fragile X premutation presenting as essential tremor. <i>Archives of Neurology</i> , 2003 , 60, 117-21		145
848	Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. <i>Neurology</i> , 2019 , 92, 329-337	6.5	144
847	Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. <i>European Journal of Neurology</i> , 2009 , 16, 297-309	6	143
846	Multiple sclerosis and extract of cannabis: results of the MUSEC trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012 , 83, 1125-32	5.5	142
845	Neuropsychological consequences of posteroventral pallidotomy for the treatment of Parkinson's disease. <i>Neurology</i> , 1998 , 51, 207-15	6.5	142

844	Genotype-phenotype correlation of paroxysmal nonkinesigenic dyskinesia. <i>Neurology</i> , 2007 , 68, 1782-9	6.5	141
843	Lidocaine and muscimol microinjections in subthalamic nucleus reverse Parkinsonian symptoms. <i>Brain</i> , 2001 , 124, 2105-18	11.2	141
842	Parkinson's disease subtypes: lost in translation?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013 , 84, 409-15	5.5	138
841	A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. <i>Movement Disorders</i> , 2008 , 23, 2194-201	7	138
840	Neurophysiological effects of stimulation through electrodes in the human subthalamic nucleus. <i>Brain</i> , 1999 , 122 (Pt 10), 1919-31	11.2	138
839	Parkinson's disease and depression. A critical re-evaluation. <i>Brain</i> , 1986 , 109 (Pt 2), 279-92	11.2	135
838	Painful Parkinson's disease. <i>Lancet, The</i> , 1986 , 1, 1366-9	4.0	133
837	Toward a redefinition of Parkinson's disease. <i>Movement Disorders</i> , 2012 , 27, 54-60	7	132
836	Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease. <i>Archives of Neurology</i> , 2004 , 61, 1898-904		131
835	Evidence for inter-generational instability in the CAG repeat in the MJD1 gene and for conserved haplotypes at flanking markers amongst Japanese and Caucasian subjects with Machado-Joseph disease. <i>Human Molecular Genetics</i> , 1995 , 4, 1137-46	5.6	129
834	Overview of the extranigral aspects of Parkinson disease. <i>Archives of Neurology</i> , 2009 , 66, 167-72		128
833	The spectrum of levodopa-related fluctuations in Parkinson's disease. <i>Neurology</i> , 1993 , 43, 1459-64	6.5	128
832	Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson's disease?. <i>Neuropsychopharmacology</i> , 2009 , 34, 2758-66	8.7	126
831	Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers. <i>Neurology</i> , 2011 , 77, 325-33	6.5	126
830	Relationship of lesion location to clinical outcome following microelectrode-guided pallidotomy for Parkinson's disease. <i>Brain</i> , 1999 , 122 (Pt 3), 405-16	11.2	122
829	Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts. <i>Annals of Neurology</i> , 2018 , 84, 797-811	9.4	122
828	Imaging biomarkers in Parkinson's disease and Parkinsonian syndromes: current and emerging concepts. <i>Translational Neurodegeneration</i> , 2017 , 6, 8	10.3	121
827	Deep brain stimulation for Parkinson's disease: patient selection and evaluation. <i>Movement Disorders</i> , 2002 , 17 Suppl 3, S94-101	7	121

826	Gender-related penetrance and de novo GTP-cyclohydrolase I gene mutations in dopa-responsive dystonia. <i>Neurology</i> , 1998 , 50, 1015-20	6.5	121
825	Myoclonic dystonia. <i>Neurology</i> , 1983 , 33, 825-30	6.5	119
824	Psychogenic dystonia: a review of 18 cases. <i>Canadian Journal of Neurological Sciences</i> , 1995 , 22, 136-43	1	118
823	Hypoxic-ischemic damage of the basal ganglia. Case reports and a review of the literature. <i>Movement Disorders</i> , 1990 , 5, 219-24	7	118
822	Opinions and clinical practices related to diagnosing and managing patients with psychogenic movement disorders: An international survey of movement disorder society members. <i>Movement Disorders</i> , 2009 , 24, 1366-74	7	117
821	Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. <i>Movement Disorders</i> , 2006 , 21, 1844-50	7	116
820	Psychogenic parkinsonism. <i>Archives of Neurology</i> , 1995 , 52, 802-10		116
819	Effects of subthalamic nucleus stimulation on motor cortex excitability in Parkinson's disease. <i>Neurology</i> , 2002 , 58, 1665-72	6.5	115
818	Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort. <i>Neurology</i> , 2005 , 64, 87-93	6.5	114
817	A novel locus for inherited myoclonus-dystonia on 18p11. <i>Neurology</i> , 2002 , 59, 1183-6	6.5	114
816	Parkinson disease in 2015: Evolving basic, pathological and clinical concepts in PD. <i>Nature Reviews Neurology</i> , 2016 , 12, 65-6	15	113
815	Unusual clinical presentations of cortical-basal ganglionic degeneration. <i>Annals of Neurology</i> , 1996 , 40, 893-900	9.4	113
814	Patient perception of tics and other movement disorders. <i>Neurology</i> , 1991 , 41, 223-8	6.5	113
813	Psychiatric outcome in patients with a psychogenic movement disorder: a prospective study. <i>Neuropsychiatry, Neuropsychology and Behavioral Neurology</i> , 2001 , 14, 169-76		113
812	Myoclonus-dystonia: significance of large SGCE deletions. <i>Human Mutation</i> , 2008 , 29, 331-2	4.7	112
811	Potentials recorded at the scalp by stimulation near the human subthalamic nucleus. <i>Clinical Neurophysiology</i> , 2001 , 112, 431-7	4.3	112
810	Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials. <i>Movement Disorders</i> , 2017 , 32, 319-324	7	111
809	Mutations in SLC20A2 are a major cause of familial idiopathic basal ganglia calcification. <i>Neurogenetics</i> , 2013 , 14, 11-22	3	111

808	Colonic mucosal a-synuclein lacks specificity as a biomarker for Parkinson disease. <i>Neurology</i> , 2015 , 84, 609-16	6.5	110
807	Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial. <i>Movement Disorders</i> , 2008 , 23, 653-9; quiz 776	7	109
806	Neuronal firing rates and patterns in the globus pallidus internus of patients with cervical dystonia differ from those with Parkinson's disease. <i>Journal of Neurophysiology</i> , 2007 , 98, 720-9	3.2	109
805	Networks mediating the clinical effects of pallidal brain stimulation for Parkinson's disease: a PET study of resting-state glucose metabolism. <i>Brain</i> , 2001 , 124, 1601-9	11.2	109
804	Frozen shoulder and other shoulder disturbances in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1989 , 52, 63-6	5.5	109
803	Longitudinal follow-up of SWEDD subjects in the PRECEPT Study. <i>Neurology</i> , 2014 , 82, 1791-7	6.5	108
802	Premotor Parkinson's disease: concepts and definitions. <i>Movement Disorders</i> , 2012 , 27, 608-16	7	108
801	Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. <i>Lancet Neurology</i> , 2013 , 12, 514-24	24.1	108
800	Treatment of excessive daytime sleepiness in patients with Parkinson's disease with modafinil. <i>Clinical Neuropharmacology</i> , 2002 , 25, 111-4	1.4	108
799	AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. <i>Movement Disorders</i> , 2013 , 28, 1838-46	7	107
798	Association between early-onset Parkinson disease and 22q11.2 deletion syndrome: identification of a novel genetic form of Parkinson disease and its clinical implications. <i>JAMA Neurology</i> , 2013 , 70, 1359-66	17.2	107
797	Gait abnormalities in psychogenic movement disorders. <i>Movement Disorders</i> , 2007 , 22, 395-9	7	107
796	Progressive ataxia and palatal tremor (PAPT): clinical and MRI assessment with review of palatal tremors. <i>Brain</i> , 2004 , 127, 1252-68	11.2	107
795	Uncovering the role of the insula in non-motor symptoms of Parkinson's disease. <i>Brain</i> , 2014 , 137, 2143-54	14.2	106
794	Large-scale replication and heterogeneity in Parkinson disease genetic loci. <i>Neurology</i> , 2012 , 79, 659-67	6.5	106
793	The importance of gene dosage studies: mutational analysis of the parkin gene in early-onset parkinsonism. <i>Human Molecular Genetics</i> , 2001 , 10, 1649-56	5.6	106
792	Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. <i>Annals of Neurology</i> , 2010 , 68, 963-8	9.4	105
791	Emergence of restless legs syndrome during subthalamic stimulation for Parkinson disease. <i>Neurology</i> , 2004 , 63, 2410-2	6.5	105

790	Dopa-responsive parkinsonism phenotype of Machado-Joseph disease: confirmation of 14q CAG expansion. <i>Annals of Neurology</i> , 1995 , 38, 684-7	9.4	105
789	Posttraumatic movement disorders: a review. <i>Movement Disorders</i> , 1989 , 4, 20-36	7	104
788	Precision medicine for disease modification in Parkinson disease. <i>Nature Reviews Neurology</i> , 2017 , 13, 119-126	15	103
787	The nonmotor symptoms of Parkinson's disease--an overview. <i>Movement Disorders</i> , 2010 , 25 Suppl 1, S123-30	7	103
786	Botulinum toxin for essential tremor of the voice with multiple anatomical sites of tremor: a crossover design study of unilateral versus bilateral injection. <i>Laryngoscope</i> , 2000 , 110, 1366-74	3.6	103
785	Punding prevalence in Parkinson's disease. <i>Movement Disorders</i> , 2007 , 22, 1179-81	7	102
784	Antidepressant treatment outcomes of psychogenic movement disorder. <i>Journal of Clinical Psychiatry</i> , 2005 , 66, 1529-34	4.6	102
783	Validation of the MDS clinical diagnostic criteria for Parkinson's disease. <i>Movement Disorders</i> , 2018 , 33, 1601-1608	7	101
782	From psychogenic movement disorder to functional movement disorder: it's time to change the name. <i>Movement Disorders</i> , 2014 , 29, 849-52	7	101
781	Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson's patients with medication-induced pathological gambling: a [11C] FLB-457 and PET study. <i>Neurobiology of Disease</i> , 2012 , 48, 519-25	7.5	101
780	A critical appraisal of the premotor symptoms of Parkinson's disease: potential usefulness in early diagnosis and design of neuroprotective trials. <i>Movement Disorders</i> , 2011 , 26, 775-83	7	101
779	The nature and time course of cortical activation following subthalamic stimulation in Parkinson's disease. <i>Cerebral Cortex</i> , 2010 , 20, 1926-36	5.1	100
778	Intracranial hypotension with parkinsonism, ataxia, and bulbar weakness. <i>Archives of Neurology</i> , 1999 , 56, 869-72		99
777	Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohorts. <i>Lancet Neurology</i> , 2017 , 16, 620-629	24.1	98
776	Combined insular and striatal dopamine dysfunction are associated with executive deficits in Parkinson's disease with mild cognitive impairment. <i>Brain</i> , 2014 , 137, 565-75	11.2	98
775	Whispering dysphonia (DYT4 dystonia) is caused by a mutation in the TUBB4 gene. <i>Annals of Neurology</i> , 2013 , 73, 537-45	9.4	98
774	Gut-brain axis and the spread of α -synuclein pathology: Vagal highway or dead end?. <i>Movement Disorders</i> , 2019 , 34, 307-316	7	98
773	The progression of Parkinson disease: a hypothesis. <i>Neurology</i> , 2007 , 68, 948-52	6.5	96

772	Functional correlates of pallidal stimulation for Parkinson's disease. <i>Annals of Neurology</i> , 2001 , 49, 155-64	9.4	96
771	Deconstructing normal pressure hydrocephalus: Ventriculomegaly as early sign of neurodegeneration. <i>Annals of Neurology</i> , 2017 , 82, 503-513	9.4	95
770	Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. <i>Movement Disorders</i> , 2012 , 27, 1392-7	7	94
769	Analysis of the glucocerebrosidase gene in Parkinson's disease. <i>Movement Disorders</i> , 2005 , 20, 367-70	7	93
768	Subthalamic Nucleus Stimulation: Improvements in Outcome With Reprogramming. <i>Archives of Neurology</i> , 2006 , 63, 1266-1272		93
767	α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era. <i>Trends in Neurosciences</i> , 2016 , 39, 750-762	13.3	92
766	Non-dopaminergic treatments in development for Parkinson's disease. <i>Lancet Neurology</i> , 2008 , 7, 927-38	24.1	92
765	The 'essentials' of essential palatal tremor: a reappraisal of the nosology. <i>Brain</i> , 2006 , 129, 832-40	11.2	92
764	Selective enhancement of rapid eye movement sleep by deep brain stimulation of the human pons. <i>Annals of Neurology</i> , 2009 , 66, 110-4	9.4	91
763	Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure. <i>Movement Disorders</i> , 2006 , 21, 1578-94	7	91
762	Involvement of human thalamus in the preparation of self-paced movement. <i>Brain</i> , 2004 , 127, 2717-31	11.2	91
761	An investigation of the effects of subthalamic nucleus stimulation on acoustic measures of voice. <i>Movement Disorders</i> , 2000 , 15, 1132-8	7	91
760	Involvement of the cerebellothalamocortical pathway in Parkinson disease. <i>Annals of Neurology</i> , 2010 , 68, 816-24	9.4	90
759	A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. <i>Movement Disorders</i> , 2010 , 25, 1077-81	7	90
758	Progression of gait, speech and swallowing deficits in progressive supranuclear palsy. <i>Neurology</i> , 2003 , 60, 917-22	6.5	90
757	Pathogenesis-targeted, disease-modifying therapies in Parkinson disease. <i>Neurotherapeutics</i> , 2014 , 11, 6-23	6.4	89
756	Historical and clinical features of psychogenic tremor: a review of 70 cases. <i>Canadian Journal of Neurological Sciences</i> , 1999 , 26, 190-5	1	89
755	Which ante mortem clinical features predict progressive supranuclear palsy pathology?. <i>Movement Disorders</i> , 2017 , 32, 995-1005	7	88

754	Cerebral blood flow changes induced by pedunclopontine nucleus stimulation in patients with advanced Parkinson's disease: a [(15)O] H2O PET study. <i>Human Brain Mapping</i> , 2009 , 30, 3901-9	5.9	88
753	Interhemispheric and ipsilateral connections in Parkinson's disease: relation to mirror movements. <i>Movement Disorders</i> , 2007 , 22, 813-21	7	88
752	The etiopathogenesis of Parkinson disease and suggestions for future research. Part I. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007 , 66, 251-7	3.1	88
751	Placebo effect of medication cost in Parkinson disease: a randomized double-blind study. <i>Neurology</i> , 2015 , 84, 794-802	6.5	87
750	Levodopa response in long-term bilateral subthalamic stimulation for Parkinson's disease. <i>Movement Disorders</i> , 2007 , 22, 990-7	7	87
749	Manganese-induced Parkinsonism associated with methcathinone (Ephedrone) abuse. <i>Archives of Neurology</i> , 2007 , 64, 886-9		87
748	Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013 , 84, 130-5	5.5	86
747	Parkinson's disease. Cognitive changes in relation to treatment response. <i>Brain</i> , 1987 , 110 (Pt 1), 35-51	11.2	86
746	Extrastriatal dopaminergic dysfunction in tourette syndrome. <i>Annals of Neurology</i> , 2010 , 67, 170-81	9.4	84
745	Orthostatic tremor arises from an oscillator in the posterior fossa. <i>Movement Disorders</i> , 2001 , 16, 272-9	7	84
744	Investigation of c9orf72 in 4 neurodegenerative disorders. <i>Archives of Neurology</i> , 2012 , 69, 1583-90		83
743	Dystonia in progressive supranuclear palsy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1997 , 62, 352-6	5.5	83
742	The cerebellothalamocortical pathway in essential tremor. <i>Neurology</i> , 2003 , 60, 1985-7	6.5	83
741	Adult-onset subacute sclerosing panencephalitis: case reports and review of the literature. <i>Movement Disorders</i> , 1997 , 12, 342-53	7	82
740	Benign hereditary chorea: clinical, genetic, and pathological findings. <i>Annals of Neurology</i> , 2003 , 54, 244-54	9.4	81
739	Bioinformatics-Based Identification of Expanded Repeats: A Non-reference Intronic Pentamer Expansion in RFC1 Causes CANVAS. <i>American Journal of Human Genetics</i> , 2019 , 105, 151-165	11	80
738	Characterization of REM-sleep associated ponto-geniculo-occipital waves in the human pons. <i>Sleep</i> , 2007 , 30, 823-7	1.1	80
737	Bilateral globus pallidus internus deep brain stimulation in tardive dyskinesia: a case report. <i>Movement Disorders</i> , 2004 , 19, 969-72	7	80

736	Relationship of lesion location to cognitive outcome following microelectrode-guided pallidotomy for Parkinson's disease: support for the existence of cognitive circuits in the human pallidum. <i>Brain</i> , 2000 , 123 (Pt 4), 746-58	11.2	79
735	Phenotype-specific diagnosis of functional (psychogenic) movement disorders. <i>Current Neurology and Neuroscience Reports</i> , 2015 , 15, 32	6.6	78
734	Helicobacter pylori infection is associated with worse severity of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 221-5	3.6	78
733	A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants. <i>Journal of Medical Genetics</i> , 2012 , 49, 721-6	5.8	78
732	The many faces of corticobasal degeneration. <i>Parkinsonism and Related Disorders</i> , 2007 , 13 Suppl 3, S336-40	3.4	78
731	Effects of internal globus pallidus stimulation on motor cortex excitability. <i>Neurology</i> , 2001 , 56, 716-23	6.5	78
730	Neurogenic orthostatic hypotension and supine hypertension in Parkinson's disease and related synucleinopathies: prioritisation of treatment targets. <i>Lancet Neurology</i> , 2016 , 15, 954-966	24.1	78
729	Do dyskinesia and pain share common pathophysiological mechanisms in Parkinson's disease?. <i>Movement Disorders</i> , 2008 , 23, 1689-95	7	77
728	The treatment of dystonic tremor: a systematic review. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, 759-69	5.5	76
727	Stereotypies: a critical appraisal and suggestion of a clinically useful definition. <i>Movement Disorders</i> , 2012 , 27, 179-85	7	74
726	Palliative care for advanced Parkinson disease: an interdisciplinary clinic and new scale, the ESAS-PD. <i>Parkinsonism and Related Disorders</i> , 2012 , 18 Suppl 3, S6-9	3.6	74
725	Olfactory dysfunction in familial parkinsonism. <i>Neurology</i> , 1997 , 49, 1262-7	6.5	74
724	New developments in understanding the etiology of Parkinson's disease and in its treatment. <i>Current Opinion in Neurobiology</i> , 1998 , 8, 783-90	7.6	74
723	Corticobasal ganglionic degeneration and progressive supranuclear palsy presenting with cognitive decline. <i>Brain Pathology</i> , 1998 , 8, 355-65	6	74
722	Psychogenic facial movement disorders: clinical features and associated conditions. <i>Movement Disorders</i> , 2012 , 27, 1544-51	7	73
721	Unilateral subdural motor cortex stimulation improves essential tremor but not Parkinson's disease. <i>Brain</i> , 2011 , 134, 2096-105	11.2	73
720	Homozygous inheritance of the Machado-Joseph disease gene. <i>Annals of Neurology</i> , 1994 , 36, 443-7	9.4	73
719	Stimulus-sensitive myoclonus in akinetic-rigid syndromes. <i>Brain</i> , 1992 , 115 (Pt 6), 1875-88	11.2	73

7 ¹⁸	Multiple system atrophy-parkinsonism with slow progression and prolonged survival: a diagnostic catch. <i>Movement Disorders</i> , 2012 , 27, 1186-90	7	72
7 ¹⁷	Mirror movements in parkinsonism: evaluation of a new clinical sign. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005 , 76, 1355-8	5.5	72
7 ¹⁶	Surgery for Parkinson disease: A critical evaluation of the state of the art. <i>Archives of Neurology</i> , 2000 , 57, 1118-25		72
7 ¹⁵	Chronic acquired hepatocerebral degeneration: case reports and new insights. <i>Movement Disorders</i> , 1995 , 10, 714-22	7	72
7 ¹⁴	Management of impulse control disorders in Parkinson's disease: Controversies and future approaches. <i>Movement Disorders</i> , 2015 , 30, 150-9	7	71
7 ¹³	Impairments of speed and amplitude of movement in Parkinson's disease: a pilot study. <i>Movement Disorders</i> , 2009 , 24, 1001-8	7	71
7 ¹²	Inhibition of voluntary activity by thalamic stimulation in humans: relevance for the control of tremor. <i>Movement Disorders</i> , 1997 , 12, 727-37	7	71
7 ¹¹	Levodopa-related motor complications--phenomenology. <i>Movement Disorders</i> , 2008 , 23 Suppl 3, S509-14		71
7 ¹⁰	Impairment of motor cortex activation and deactivation in Parkinson's disease. <i>Clinical Neurophysiology</i> , 2001 , 112, 600-7	4.3	71
7 ⁰⁹	Parietal Pick's disease mimicking cortical-basal ganglionic degeneration. <i>Neurology</i> , 1994 , 44, 1436-40	6.5	71
7 ⁰⁸	Cortical Degeneration in Progressive Supranuclear Palsy. A Comparison with Cortical-Basal Ganglionic Degeneration. <i>Journal of Neuropathology and Experimental Neurology</i> , 1997 , 56, 726-734	3.1	71
7 ⁰⁷	Dopaminergic transplantation for Parkinson's disease: current status and future prospects. <i>Annals of Neurology</i> , 2009 , 66, 591-6	9.4	70
7 ⁰⁶	Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations. <i>Movement Disorders</i> , 2004 , 19, 22-8	7	70
7 ⁰⁵	Caffeine as symptomatic treatment for Parkinson disease (CafEPD): A randomized trial. <i>Neurology</i> , 2017 , 89, 1795-1803	6.5	69
7 ⁰⁴	Investing in the future: stimulation of the medial prefrontal cortex reduces discounting of delayed rewards. <i>Neuropsychopharmacology</i> , 2015 , 40, 546-53	8.7	69
7 ⁰³	Tardive dyskinesia syndromes: current concepts. <i>Parkinsonism and Related Disorders</i> , 2014 , 20 Suppl 1, S113-7	3.6	69
7 ⁰²	Stimulation of the subthalamic nucleus in Parkinson's disease does not produce striatal dopamine release. <i>Neurosurgery</i> , 2003 , 53, 1095-102; discussion 1102-5	3.2	69
7 ⁰¹	Pallidal stimulation in Parkinson's disease patients with a prior unilateral pallidotomy. <i>Canadian Journal of Neurological Sciences</i> , 1998 , 25, 300-5	1	69

700	Psychogenic dyskinesias in patients with organic movement disorders. <i>Movement Disorders</i> , 1990 , 5, 127-33	69
699	Posttraumatic painful torticollis. <i>Movement Disorders</i> , 2003 , 18, 1482-91	7 68
698	Mutation analysis of CHCHD10 in different neurodegenerative diseases. <i>Brain</i> , 2015 , 138, e380	11.2 67
697	Movement disorder society criteria for clinically established early Parkinson's disease. <i>Movement Disorders</i> , 2018 , 33, 1643-1646	7 67
696	Imaging Striatal Microglial Activation in Patients with Parkinson's Disease. <i>PLoS ONE</i> , 2015 , 10, e0138721	3.7 67
695	Psychogenic movement disorders. <i>Canadian Journal of Neurological Sciences</i> , 2003 , 30 Suppl 1, S94-100	1 67
694	Firing rates of pallidal neurons are similar in Huntington's and Parkinson's disease patients. <i>Experimental Brain Research</i> , 2005 , 166, 230-6	2.3 66
693	Invited article: changing concepts in Parkinson disease: moving beyond the decade of the brain. <i>Neurology</i> , 2008 , 70, 1996-2003	6.5 65
692	Clinical features differentiating patients with postmortem confirmed progressive supranuclear palsy and corticobasal degeneration. <i>Journal of Neurology</i> , 1999 , 246 Suppl 2, II1-5	5.5 65
691	Dopamine Agonists Diminish Value Sensitivity of the Orbitofrontal Cortex: A Trigger for Pathological Gambling in Parkinson's Disease?. <i>Neuropsychopharmacology</i> , 2009 , 34, 2758-66	8.7 65
690	Integrated safety of levodopa-carbidopa intestinal gel from prospective clinical trials. <i>Movement Disorders</i> , 2016 , 31, 538-46	7 65
689	Alimentary, my dear Watson? The challenges of enteric β -synuclein as a Parkinson's disease biomarker. <i>Movement Disorders</i> , 2014 , 29, 444-50	7 64
688	Vascular Parkinsonism: deconstructing a syndrome. <i>Movement Disorders</i> , 2015 , 30, 886-94	7 63
687	Clinical trials of disease-modifying therapies for neurodegenerative diseases: the challenges and the future. <i>Nature Medicine</i> , 2010 , 16, 1223-6	50.5 63
686	Hemiballism in multiple sclerosis. <i>Movement Disorders</i> , 1988 , 3, 88-94	7 63
685	Parkinson's disease-related fatigue: A case definition and recommendations for clinical research. <i>Movement Disorders</i> , 2016 , 31, 625-31	7 63
684	AAV1/2-induced overexpression of A53T- β -synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease. <i>Acta Neuropathologica Communications</i> , 2017 , 5, 11	7.3 62
683	Salience network and parahippocampal dopamine dysfunction in memory-impaired Parkinson disease. <i>Annals of Neurology</i> , 2015 , 77, 269-80	9.4 62

682	Ataxia-telangiectasia: A review of movement disorders, clinical features, and genotype correlations. <i>Movement Disorders</i> , 2018 , 33, 1238-1247	7	62
681	Factor analysis of the motor section of the unified Parkinson's disease rating scale during the off-state. <i>Movement Disorders</i> , 1999 , 14, 585-9	7	62
680	Pallidal deep brain stimulation in cervical dystonia: clinical outcome in four cases. <i>Canadian Journal of Neurological Sciences</i> , 2004 , 31, 328-32	1	61
679	The new definition and diagnostic criteria of Parkinson's disease. <i>Lancet Neurology, The</i> , 2016 , 15, 546-8	24.1	61
678	Regulation of myeloid cell phagocytosis by LRRK2 via WAVE2 complex stabilization is altered in Parkinson's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, E5164-E5173	11.5	61
677	Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?. <i>Neurology</i> , 2020 , 94, 481-494	6.5	60
676	Dopamine-agonists and impulsivity in Parkinson's disease: impulsive choices vs. impulsive actions. <i>Human Brain Mapping</i> , 2014 , 35, 2499-506	5.9	59
675	Movement disorders on YouTube--caveat spectator. <i>New England Journal of Medicine</i> , 2011 , 365, 1160-159.2	59.2	59
674	Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with Synucleinopathies. <i>Neurobiology of Disease</i> , 2015 , 78, 162-71	7.5	58
673	Acute onset dystonic camptocormia caused by lenticular lesions. <i>Movement Disorders</i> , 2001 , 16, 177-80	7	57
672	Regional cerebral glucose metabolism in SLE chorea: further evidence that striatal hypometabolism is not a correlate of chorea. <i>Movement Disorders</i> , 1987 , 2, 201-10	7	57
671	Pergolide in late-stage Parkinson disease. <i>Annals of Neurology</i> , 1982 , 12, 243-7	9.4	57
670	How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. <i>Movement Disorders</i> , 2019 , 34, 1228-1232	7	56
669	Perampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's disease. <i>Movement Disorders</i> , 2012 , 27, 284-8	7	56
668	Subthalamic nucleus-deep brain stimulation for early motor complications in Parkinson's disease-the EARLYSTIM trial: early is not always better. <i>Movement Disorders</i> , 2014 , 29, 1751-6	7	56
667	Impaired presynaptic inhibition in the motor cortex in Parkinson disease. <i>Neurology</i> , 2009 , 72, 842-9	6.5	56
666	Thalamic deep brain stimulation activates the cerebellothalamocortical pathway. <i>Neurology</i> , 2004 , 63, 907-9	6.5	56
665	Parkinson's disease in the Western Pacific Region. <i>Lancet Neurology, The</i> , 2019 , 18, 865-879	24.1	55

664	Tourette syndrome. Secondary tic disorders. <i>Neurologic Clinics</i> , 1997 , 15, 309-31	4.5	55
663	Criteria for deep-brain stimulation in Parkinson's disease: review and analysis. <i>Expert Review of Neurotherapeutics</i> , 2006 , 6, 1695-705	4.3	55
662	ATP13A2 variants in early-onset Parkinson's disease patients and controls. <i>Movement Disorders</i> , 2009 , 24, 2104-11	7	54
661	Phenotypic spectrum and sex effects in eleven myoclonus-dystonia families with epsilon-sarcoglycan mutations. <i>Movement Disorders</i> , 2008 , 23, 588-92	7	54
660	Involvement of the basal ganglia and cerebellar motor pathways in the preparation of self-initiated and externally triggered movements in humans. <i>Journal of Neuroscience</i> , 2007 , 27, 6029-36	6.6	54
659	Alterations of striatal neurons in benign hereditary chorea. <i>Movement Disorders</i> , 2005 , 20, 1353-7	7	54
658	Dopa dose-dependent sexual deviation. <i>British Journal of Psychiatry</i> , 1983 , 142, 296-8	5.4	54
657	A double-blind trial of clonazepam in benign essential tremor. <i>Clinical Neuropharmacology</i> , 1984 , 7, 83-8	1.4	54
656	Factors influencing the outcome of deep brain stimulation: Placebo, nocebo, lessebo, and lesion effects. <i>Movement Disorders</i> , 2016 , 31, 290-6	7	54
655	Timing of deep brain stimulation in Parkinson disease: a need for reappraisal?. <i>Annals of Neurology</i> , 2013 , 73, 565-75	9.4	53
654	Peroxisomal D-bifunctional protein deficiency: three adults diagnosed by whole-exome sequencing. <i>Neurology</i> , 2014 , 82, 963-8	6.5	53
653	Deep brain stimulation for Parkinson's disease. <i>Movement Disorders</i> , 2006 , 21 Suppl 14, S168-70	7	53
652	Motor neuron disease-inclusion dementia presenting as cortical-basal ganglionic degeneration. <i>Movement Disorders</i> , 1999 , 14, 674-80	7	53
651	Essential pitfalls in "essential" tremor. <i>Movement Disorders</i> , 2017 , 32, 325-331	7	52
650	Behavioral effects of levodopa. <i>Movement Disorders</i> , 2015 , 30, 90-102	7	52
649	Understanding disability in Tourette syndrome. <i>Developmental Medicine and Child Neurology</i> , 2009 , 51, 468-72	3.3	52
648	Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study. <i>Neurology</i> , 2006 , 66, 1941-3	6.5	52
647	Subthalamic nucleus stimulation modulates afferent inhibition in Parkinson disease. <i>Neurology</i> , 2007 , 68, 356-63	6.5	52

646	Low-frequency repetitive transcranial magnetic stimulation for treatment of levodopa-induced dyskinesias. <i>Neurology</i> , 2007 , 68, 704-5	6.5	52
645	Initiation of pharmacological therapy in Parkinson's disease: when, why, and how. <i>Lancet Neurology, The</i> , 2020 , 19, 452-461	24.1	51
644	Fixing the broken system of genetic locus symbols: Parkinson disease and dystonia as examples. <i>Neurology</i> , 2012 , 78, 1016-24	6.5	51
643	Bilateral subthalamic stimulation in Parkin and PINK1 parkinsonism. <i>Neurology</i> , 2008 , 70, 1186-91	6.5	51
642	Impaired emotion processing in functional (psychogenic) tremor: A functional magnetic resonance imaging study. <i>NeuroImage: Clinical</i> , 2018 , 17, 179-187	5.3	50
641	Involvement of the human subthalamic nucleus in movement preparation. <i>Neurology</i> , 2003 , 61, 1538-45	6.5	50
640	Striatonigral degeneration: iron deposition in putamen correlates with the slit-like void signal of magnetic resonance imaging. <i>Canadian Journal of Neurological Sciences</i> , 1994 , 21, 311-8	1	50
639	Functional neurological disorders in Parkinson disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018 , 89, 566-571	5.5	49
638	Global investigation and meta-analysis of the C9orf72 (G4C2) _n repeat in Parkinson disease. <i>Neurology</i> , 2014 , 83, 1906-13	6.5	49
637	Hereditary parkinsonism: Parkinson disease look-alikes--an algorithm for clinicians to "PARK" genes and beyond. <i>Movement Disorders</i> , 2009 , 24, 2042-58	7	49
636	Sustained relief of dystonia following cessation of deep brain stimulation. <i>Movement Disorders</i> , 2007 , 22, 1958-62	7	49
635	Subthalamic nucleus stimulation: improvements in outcome with reprogramming. <i>Archives of Neurology</i> , 2006 , 63, 1266-72		49
634	'Under pressure': is there a link between orthostatic hypotension and cognitive impairment in Synucleinopathies?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 1311-1321	5.5	49
633	The Movement disorder associated with NMDAR antibody-encephalitis is complex and characteristic: an expert video-rating study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019 , 90, 724-726	5.5	48
632	rCBF changes associated with PPN stimulation in a patient with Parkinson's disease: a PET study. <i>Movement Disorders</i> , 2008 , 23, 1051-1054	7	48
631	Factors predictive of the need for levodopa therapy in early, untreated Parkinson's disease. The Parkinson Study Group. <i>Archives of Neurology</i> , 1995 , 52, 565-70		48
630	Cortical Plasticity Induction by Pairing Subthalamic Nucleus Deep-Brain Stimulation and Primary Motor Cortical Transcranial Magnetic Stimulation in Parkinson's Disease. <i>Journal of Neuroscience</i> , 2016 , 36, 396-404	6.6	47
629	Altered body composition, sarcopenia, frailty, and their clinico-biological correlates, in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018 , 56, 58-64	3.6	47

628	Prefrontal dopaminergic receptor abnormalities and executive functions in Parkinson's disease. <i>Human Brain Mapping</i> , 2013 , 34, 1591-604	5.9	47
627	A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY-PD III). <i>Annals of Clinical and Translational Neurology</i> , 2017 , 4, 360-368	5.3	46
626	When and how should treatment be started in Parkinson disease?. <i>Neurology</i> , 2009 , 72, S39-43	6.5	46
625	Tics and functional tic-like movements: Can we tell them apart?. <i>Neurology</i> , 2019 , 93, 750-758	6.5	45
624	Fatigue in Parkinson's disease: report from a mutidisciplinary symposium. <i>Npj Parkinson's Disease</i> , 2016 , 2,	9.7	45
623	Trial designs used to study neuroprotective therapy in Parkinson's disease. <i>Movement Disorders</i> , 2013 , 28, 86-95	7	45
622	Multiple sclerosis occurring with paroxysmal unilateral dystonia. <i>Movement Disorders</i> , 1990 , 5, 352-3	7	45
621	Botulinum toxin injections in the treatment of blepharospasm, hemifacial spasm, and eyelid fasciculations. <i>Canadian Journal of Neurological Sciences</i> , 1988 , 15, 276-80	1	45
620	The Ontario Neurodegenerative Disease Research Initiative (ONDRI). <i>Canadian Journal of Neurological Sciences</i> , 2017 , 44, 196-202	1	44
619	A critique of the second consensus criteria for multiple system atrophy. <i>Movement Disorders</i> , 2019 , 34, 975-984	7	44
618	Response to clozapine in a clinically identifiable subtype of schizophrenia. <i>British Journal of Psychiatry</i> , 2015 , 206, 484-91	5.4	44
617	Antecollis and levodopa-responsive parkinsonism are late features of Dravet syndrome. <i>Neurology</i> , 2014 , 82, 2250-1	6.5	44
616	A longitudinal program for biomarker development in Parkinson's disease: a feasibility study. <i>Movement Disorders</i> , 2009 , 24, 2081-90	7	44
615	New use for an old drug: amantadine benefits levodopa-induced dyskinesia. <i>Movement Disorders</i> , 1998 , 13, 851	7	44
614	Single pulse stimulation of the human subthalamic nucleus facilitates the motor cortex at short intervals. <i>Journal of Neurophysiology</i> , 2004 , 92, 1937-43	3.2	44
613	Treatment of progressive supranuclear palsy and corticobasal degeneration. <i>Movement Disorders</i> , 2005 , 20 Suppl 12, S83-91	7	44
612	Long-term double-blinded unilateral pedunculopontine area stimulation in Parkinson's disease. <i>Movement Disorders</i> , 2016 , 31, 1570-1574	7	44
611	Clinical and neural responses to cognitive behavioral therapy for functional tremor. <i>Neurology</i> , 2019 , 93, e1787-e1798	6.5	43

610	Movement disorders and other motor abnormalities in adults with 22q11.2 deletion syndrome. <i>American Journal of Medical Genetics, Part A</i> , 2015 , 167A, 639-45	2.5	43
609	Benign hereditary chorea revisited: a journey to understanding. <i>Movement Disorders</i> , 2007 , 22, 2297-305; quiz 2452	7	43
608	Subthalamic nucleus deep brain stimulation for parkinson's disease after successful pallidotomy: clinical and electrophysiological observations. <i>Movement Disorders</i> , 2004 , 19, 1209-14	7	43
607	Myoclonus-dystonia: classification, phenomenology, pathogenesis, and treatment. <i>Current Opinion in Neurology</i> , 2018 , 31, 484-490	7.1	43
606	Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbidities. <i>Translational Neurodegeneration</i> , 2019 , 8, 28	10.3	42
605	Reproducibility of data-driven Parkinson's disease subtypes for clinical research. <i>Parkinsonism and Related Disorders</i> , 2018 , 56, 102-106	3.6	42
604	[F]-THK5351 PET Correlates with Topology and Symptom Severity in Progressive Supranuclear Palsy. <i>Frontiers in Aging Neuroscience</i> , 2017 , 9, 440	5.3	42
603	Characteristic head drops and axial extension in advanced chorea-acanthocytosis. <i>Movement Disorders</i> , 2010 , 25, 1487-91	7	42
602	Neuropsychological and behavioral changes and weight gain after medial pallidotomy. <i>Annals of Neurology</i> , 1997 , 41, 834-6	9.4	42
601	Deep brain stimulator electrodes used for lesioning: proof of principle. <i>Neurosurgery</i> , 2001 , 49, 363-7; discussion 367-9	3.2	42
600	Anticholinergics in adult-onset focal dystonia. <i>Canadian Journal of Neurological Sciences</i> , 1982 , 9, 313-9	1	42
599	Caffeine consumption and risk of dyskinesia in CALM-PD. <i>Movement Disorders</i> , 2013 , 28, 380-3	7	41
598	Changes in cortical and pallidal oscillatory activity during the execution of a sensory trick in patients with cervical dystonia. <i>Experimental Neurology</i> , 2007 , 204, 845-8	5.7	41
597	Psychogenic movement disorders. <i>Current Opinion in Neurology</i> , 2005 , 18, 399-404	7.1	41
596	Psychiatric symptoms in patients with Parkinson disease presenting for deep brain stimulation surgery. <i>Journal of Neurosurgery</i> , 2005 , 103, 246-51	3.2	41
595	Immediate motor effects of stimulation through electrodes implanted in the human globus pallidus. <i>Stereotactic and Functional Neurosurgery</i> , 1998 , 70, 1-18	1.6	41
594	Movement sequencing disorders in Parkinson's disease. <i>International Journal of Neuroscience</i> , 1993 , 73, 183-94	2	41
593	Persistent hemiballismus with lesions outside the subthalamic nucleus. <i>Canadian Journal of Neurological Sciences</i> , 1985 , 12, 125-8	1	41

592	Secondary dystonia. <i>Advances in Neurology</i> , 1988 , 50, 9-33		41
591	Common Myths in the Use of Levodopa in Parkinson Disease: When Clinical Trials Misinform Clinical Practice. <i>JAMA Neurology</i> , 2017 , 74, 633-634	17.2	40
590	Motor Phenotype in Neurodegenerative Disorders: Gait and Balance Platform Study Design Protocol for the Ontario Neurodegenerative Research Initiative (ONDRI). <i>Journal of Alzheimer's Disease</i> , 2017 , 59, 707-721	4.3	40
589	Pallidotomy for Parkinson's Disease. <i>Neurosurgery Clinics of North America</i> , 1998 , 9, 325-336	4	40
588	Familial dystonia and visual failure with striatal CT lucencies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1986 , 49, 500-9	5.5	40
587	Postanoxic symptomatic oscillatory myoclonus. <i>Neurology</i> , 1983 , 33, 240-3	6.5	40
586	Mutations in the epsilon-sarcoglycan gene found to be uncommon in seven myoclonus-dystonia families. <i>Neurology</i> , 2003 , 61, 244-6	6.5	39
585	Syringomyelic dystonia and athetosis. <i>Movement Disorders</i> , 1999 , 14, 684-8	7	39
584	Afferents contributing to the exaggerated long latency reflex response to electrical stimulation in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1988 , 51, 1405-10	5.5	39
583	Alcohol and Parkinson disease. <i>Annals of Neurology</i> , 1982 , 12, 254-6	9.4	39
582	Positron emission tomography imaging of tau pathology in progressive supranuclear palsy. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017 , 37, 3150-3160	7.3	38
581	Psychogenic movement disorders: past developments, current status, and future directions. <i>Movement Disorders</i> , 2011 , 26, 1175-86	7	38
580	Patient perception of dyskinesia in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010 , 81, 1112-5	5.5	38
579	Refinement of the DYT15 locus in myoclonus dystonia. <i>Movement Disorders</i> , 2007 , 22, 888-92	7	38
578	The etiopathogenesis of Parkinson disease and suggestions for future research. Part II. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007 , 66, 329-36	3.1	38
577	Appendectomy in mid and later life and risk of Parkinson's disease: A population-based study. <i>Movement Disorders</i> , 2016 , 31, 1243-7	7	38
576	Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study. <i>Brain</i> , 2016 , 139, 2050-62	11.2	38
575	Parkinson Diseases in the 2020s and Beyond: Replacing Clinico-Pathologic Convergence With Systems Biology Divergence. <i>Journal of Parkinson's Disease</i> , 2018 , 8, S59-S64	5.3	38

574	Dystonia and Parkinson's disease: What is the relationship?. <i>Neurobiology of Disease</i> , 2019 , 132, 104462	7.5	37
573	Outcome measurement in functional neurological disorder: a systematic review and recommendations. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020 , 91, 638-649	5.5	37
572	Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations. <i>Lancet Neurology, The</i> , 2012 , 11, 643-50	24.1	37
571	Prenatal and perinatal morbidity in children with Tourette syndrome and attention-deficit hyperactivity disorder. <i>Journal of Developmental and Behavioral Pediatrics</i> , 2009 , 30, 115-21	2.4	37
570	Presentation of Creutzfeldt-Jakob disease as acute corticobasal degeneration syndrome. <i>Movement Disorders</i> , 2004 , 19, 948-9	7	37
569	Changes in cortical excitability with thalamic deep brain stimulation. <i>Neurology</i> , 2005 , 64, 1913-9	6.5	37
568	A writing device improves writing in primary writing tremor. <i>Neurology</i> , 2005 , 64, 1648-50	6.5	37
567	Inherited myoclonus-dystonia: evidence supporting genetic heterogeneity. <i>Movement Disorders</i> , 2001 , 16, 106-10	7	37
566	Cortical basal ganglionic degeneration presenting with "progressive loss of speech output and orofacial dyspraxia". <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1992 , 55, 1101	5.5	37
565	Pallidal deep brain stimulation modulates cortical excitability and plasticity. <i>Annals of Neurology</i> , 2018 , 83, 352-362	9.4	36
564	Associated movement disorders in orthostatic tremor. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012 , 83, 725-9	5.5	36
563	Impact of mild cognitive impairment on health-related quality of life in Parkinson's disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2013 , 36, 67-75	2.6	36
562	Reflex myoclonus in cortical-basal ganglionic degeneration involves a transcortical pathway. <i>Movement Disorders</i> , 1997 , 12, 360-9	7	36
561	Motor cortical stimulation for parkinsonism in multiple system atrophy. <i>Archives of Neurology</i> , 2003 , 60, 1554-8		36
560	Can the Lombard effect be used to improve low voice intensity in Parkinson's disease?. <i>International Journal of Language and Communication Disorders</i> , 1992 , 27, 121-7	2.9	36
559	Imaging changes associated with cognitive abnormalities in Parkinson's disease. <i>Brain Structure and Function</i> , 2015 , 220, 2249-61	4	35
558	Unusual tremor syndromes: know in order to recognise. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 1191-1203	5.5	35
557	Perioperative problems in Parkinson's disease and their management: apomorphine with rectal domperidone. <i>Canadian Journal of Neurological Sciences</i> , 1996 , 23, 198-203	1	35

556	Disrupted Nodal and Hub Organization Account for Brain Network Abnormalities in Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2016 , 8, 259	5.3	35
555	Abolishing the 1-year rule: How much evidence will be enough?. <i>Movement Disorders</i> , 2016 , 31, 1623-1627		35
554	Effects of subthalamic nucleus stimulation on motor cortex plasticity in Parkinson disease. <i>Neurology</i> , 2015 , 85, 425-32	6.5	34
553	Altered gut microbiome and metabolome in patients with multiple system atrophy. <i>Movement Disorders</i> , 2018 , 33, 174-176	7	34
552	Emotion Detection Deficits and Decreased Empathy in Patients with Alzheimer's Disease and Parkinson's Disease Affect Caregiver Mood and Burden. <i>Frontiers in Aging Neuroscience</i> , 2018 , 10, 120	5.3	34
551	Acquired neurosyphilis presenting as movement disorders. <i>Movement Disorders</i> , 2012 , 27, 690-5	7	34
550	The curious case of phenocopies in families with genetic Parkinson's disease. <i>Movement Disorders</i> , 2011 , 26, 1793-802	7	34
549	The spectrum of orolingual tremor--a proposed classification system. <i>Movement Disorders</i> , 2008 , 23, 159-67	7	34
548	Electrophysiological features of myoclonus-dystonia. <i>Movement Disorders</i> , 2008 , 23, 2055-61	7	34
547	Corticobasal degeneration: selected developments. <i>Movement Disorders</i> , 2003 , 18 Suppl 6, S51-6	7	34
546	Evaluation of the role of the D2 dopamine receptor in myoclonus dystonia. <i>Annals of Neurology</i> , 2000 , 47, 369-373	9.4	34
545	Variability in lesion location after microelectrode-guided pallidotomy for Parkinson's disease: anatomical, physiological, and technical factors that determine lesion distribution. <i>Journal of Neurosurgery</i> , 1999 , 90, 468-77	3.2	34
544	Treatment of Parkinson's disease with agents other than levodopa and dopamine agonists: controversies and new approaches. <i>Canadian Journal of Neurological Sciences</i> , 1984 , 11, 210-20	1	34
543	Unilateral versus bilateral botulinum toxin injections in spasmodic dysphonia: acoustic and perceptual results. <i>The Journal of Otolaryngology</i> , 1993 , 22, 171-5		34
542	Gut Microbial Ecosystem in Parkinson Disease: New Clinicobiological Insights from Multi-Omics. <i>Annals of Neurology</i> , 2021 , 89, 546-559	9.4	34
541	Essential tremor plus is more common than essential tremor: Insights from the reclassification of a cohort of patients with lower limb tremor. <i>Parkinsonism and Related Disorders</i> , 2018 , 56, 109-110	3.6	33
540	Surgical correction of kyphosis in patients with camptocormia due to Parkinson's disease: a retrospective evaluation. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011 , 82, 364-8	5.5	33
539	Effects of acute stimulation through contacts placed on the motor cortex for chronic stimulation. <i>Clinical Neurophysiology</i> , 2002 , 113, 635-41	4.3	33

538	"Signing tics"--insights into the pathophysiology of symptoms in Tourette's syndrome. <i>Annals of Neurology</i> , 1993 , 33, 212-5	9.4	33
537	High dose anticholinergic therapy in adult dystonia. <i>Canadian Journal of Neurological Sciences</i> , 1986 , 13, 42-6	1	33
536	Outcome Measures for Functional Neurological Disorder: A Review of the Theoretical Complexities. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2020 , 32, 33-42	2.7	33
535	Another face of placebo: the lessebo effect in Parkinson disease: meta-analyses. <i>Neurology</i> , 2014 , 82, 1402-9	6.5	32
534	Long-term subthalamic nucleus stimulation improves sensorimotor integration and proprioception. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013 , 84, 1020-8	5.5	32
533	Pardoprunox in early Parkinson's disease: results from 2 large, randomized double-blind trials. <i>Movement Disorders</i> , 2011 , 26, 1464-76	7	32
532	Caffeine in Parkinson's disease: a pilot open-label, dose-escalation study. <i>Movement Disorders</i> , 2011 , 26, 2427-31	7	32
531	Dose-induced penile erections in response to ropinirole therapy for Parkinson's disease. <i>Movement Disorders</i> , 1999 , 14, 701-2	7	32
530	Movement disorder society unified Parkinson disease rating scale experiences in daily living: longitudinal changes and correlation with other assessments. <i>Movement Disorders</i> , 2013 , 28, 1980-6	7	31
529	Posteroventral medial pallidotomy in Parkinson's disease. <i>Journal of Neurology</i> , 1999 , 246 Suppl 2, 1128-41.5	4.5	31
528	Neuroimaging and clinical features in adults with a 22q11.2 deletion at risk of Parkinson's disease. <i>Brain</i> , 2017 , 140, 1371-1383	11.2	30
527	Minimal change multiple system atrophy: an aggressive variant?. <i>Movement Disorders</i> , 2015 , 30, 960-7	7	30
526	Restless genital syndrome in Parkinson disease. <i>JAMA Neurology</i> , 2014 , 71, 1559-61	17.2	30
525	Coexistence of tics and parkinsonism: evidence for non-dopaminergic mechanisms in tic pathogenesis. <i>Neurology</i> , 1997 , 49, 1699-701	6.5	30
524	Subdural motor cortex stimulation in Parkinson's disease does not modify movement-related rCBF pattern. <i>Movement Disorders</i> , 2007 , 22, 2113-6	7	30
523	Dystonia as a presenting sign of spinocerebellar ataxia type 1. <i>Movement Disorders</i> , 2004 , 19, 586-7	7	30
522	Identification of a VPS13A founder mutation in French Canadian families with chorea-acanthocytosis. <i>Neurogenetics</i> , 2005 , 6, 151-8	3	30
521	The core assessment program for intracerebral transplantation. <i>Movement Disorders</i> , 1995 , 10, 527-8	7	30

520	Parkinsonism in alcohol withdrawal: a follow-up study. <i>Movement Disorders</i> , 1990 , 5, 36-9	7	30
519	Progressive dystonia with bilateral putaminal hypodensities. <i>Archives of Neurology</i> , 1987 , 44, 1184-7		30
518	A rostrocaudal gradient for aromatic acid decarboxylase in the human striatum. <i>Canadian Journal of Neurological Sciences</i> , 1987 , 14, 444-7	1	30
517	Deficits in the Mimicry of Facial Expressions in Parkinson's Disease. <i>Frontiers in Psychology</i> , 2016 , 7, 780	3.4	30
516	Contribution of insula in Parkinson's disease: A quantitative meta-analysis study. <i>Human Brain Mapping</i> , 2016 , 37, 1375-92	5.9	30
515	The long-term outcome of orthostatic tremor. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 167-72	5.5	29
514	[F]AV-1451 binding to neuromelanin in the substantia nigra in PD and PSP. <i>Brain Structure and Function</i> , 2018 , 223, 589-595	4	29
513	GDNF in treatment of Parkinson's disease: response to editorial. <i>Lancet Neurology, The</i> , 2006 , 5, 200-2	24.1	29
512	Withdrawal akathisia: case reports and a proposed classification of chronic akathisia. <i>Movement Disorders</i> , 1994 , 9, 188-92	7	29
511	Hemiatrophy, juvenile-onset exertional alternating leg paresis, hypotonia, and hemidystonia and adult-onset hemiparkinsonism: the spectrum of hemiparkinsonism-hemiatrophy syndrome. <i>Movement Disorders</i> , 1995 , 10, 489-95	7	29
510	Early onset of the "on-off" phenomenon in children with symptomatic Parkinsonism. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1982 , 45, 823-5	5.5	29
509	Probiotics for Constipation in Parkinson Disease: A Randomized Placebo-Controlled Study. <i>Neurology</i> , 2021 , 96, e772-e782	6.5	29
508	Surgery for levodopa-induced dyskinesias. <i>Annals of Neurology</i> , 2000 , 47, S193-9; discussion S199-202	9.4	29
507	The Parkinson's disease e-diary: Developing a clinical and research tool for the digital age. <i>Movement Disorders</i> , 2019 , 34, 676-681	7	28
506	GDNF and Parkinson's Disease: Where Next? A Summary from a Recent Workshop. <i>Journal of Parkinson's Disease</i> , 2020 , 10, 875-891	5.3	28
505	What is "essential" about essential tremor? A diagnostic placeholder. <i>Movement Disorders</i> , 2018 , 33, 58-61		28
504	Tremor retraining as therapeutic strategy in psychogenic (functional) tremor. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 647-50	3.6	28
503	Pardoprinox as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trial. <i>Parkinsonism and Related Disorders</i> , 2012 , 18, 370-6	3.6	28

502	Movement disorders in patients with diabetes mellitus. <i>Journal of the Neurological Sciences</i> , 2012 , 314, 5-11	3.2	28
501	Unilateral versus bilateral tasks in early asymmetric Parkinson's disease: differential effects on bradykinesia. <i>Movement Disorders</i> , 2007 , 22, 328-33	7	28
500	Neurodegenerative disease and the evolution of art: the effects of presumed corticobasal degeneration in a professional artist. <i>Movement Disorders</i> , 2003 , 18, 294-302	7	28
499	Genetic association study of PINK1 coding polymorphisms in Parkinson's disease. <i>Neuroscience Letters</i> , 2004 , 372, 226-9	3.3	28
498	Dementia prevalence in Parkinson's disease. <i>Lancet, The</i> , 1985 , 1, 1037	40	28
497	Double-blind study of pramipexole, a new partial dopamine agonist, in early Parkinson's disease. <i>Movement Disorders</i> , 2010 , 25, 738-46	7	27
496	Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. <i>Neurology</i> , 2008 , 71, 462; author reply 462-3	6.5	27
495	Gestes antagonistes in psychogenic dystonia. <i>Movement Disorders</i> , 2004 , 19, 331-2	7	27
494	Natural history of Oppenheim's dystonia (DYT1) in Israel. <i>Journal of Child Neurology</i> , 2003 , 18, 325-30	2.5	27
493	Alcohol improves cerebellar learning deficit in myoclonus-dystonia: A clinical and electrophysiological investigation. <i>Annals of Neurology</i> , 2017 , 82, 543-553	9.4	26
492	Cannabinoid, CB1 agonists in cervical dystonia: Failure in a phase IIa randomized controlled trial. <i>Basal Ganglia</i> , 2011 , 1, 91-95		26
491	Opinions and clinical practices related to diagnosing and managing functional (psychogenic) movement disorders: changes in the last decade. <i>European Journal of Neurology</i> , 2020 , 27, 975-984	6	25
490	Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11.2. <i>Neurology</i> , 2018 , 90, e2059-e2067	6.5	25
489	Large deletions account for an increasing number of mutations in SGCE. <i>Movement Disorders</i> , 2008 , 23, 456-60	7	25
488	Essential palatal tremor: evidence of heterogeneity based on clinical features and response to Sumatriptan. <i>Movement Disorders</i> , 1999 , 14, 179-80	7	25
487	What Is the Role of a Specialist Assessment Clinic for FND? Lessons From Three National Referral Centers. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2020 , 32, 79-84	2.7	25
486	Mutation analysis of patients with neurodegenerative disorders using NeuroX array. <i>Neurobiology of Aging</i> , 2015 , 36, 545.e9-14	5.6	24
485	Orthostatic hypotension, cerebral hypoperfusion, and visuospatial deficits in Lewy body disorders. <i>Parkinsonism and Related Disorders</i> , 2016 , 22, 80-6	3.6	24

484	The perioperative management of Parkinson's disease revisited. <i>Neurologic Clinics</i> , 2004 , 22, 367-77	4.5	24
483	Phenocopies in a large GCH1 mutation positive family with dopa responsive dystonia: confusing the picture?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2002 , 72, 801-4	5.5	24
482	Oculogyric crises: A review of phenomenology, etiology, pathogenesis, and treatment. <i>Movement Disorders</i> , 2017 , 32, 193-202	7	23
481	The value of GRE, ADC and routine MRI in distinguishing Parkinsonian disorders. <i>Canadian Journal of Neurological Sciences</i> , 2013 , 40, 389-402	1	23
480	Pallidal and thalamic surgery for Parkinson's disease. <i>Experimental Neurology</i> , 1997 , 144, 35-40	5.7	23
479	Antipsychotic use in older adults with Parkinson's disease. <i>Movement Disorders</i> , 2007 , 22, 319-23	7	23
478	Homozygous and heterozygous PINK1 mutations: considerations for diagnosis and care of Parkinson's disease patients. <i>Movement Disorders</i> , 2006 , 21, 875-9	7	23
477	Isolated diaphragmatic tremor: is there a spectrum in "respiratory myoclonus"?. <i>Neurology</i> , 2007 , 69, 689-92	6.5	23
476	Clinical findings in a large family with a parkin ex3delta40 mutation. <i>Archives of Neurology</i> , 2004 , 61, 701-4		23
475	Pallidal deep brain stimulation influences both reflexive and voluntary saccades in Huntington's disease. <i>Movement Disorders</i> , 2005 , 20, 371-7	7	23
474	Late adult onset chorea with typical pathology of Hallervorden-Spatz syndrome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2000 , 69, 392-5	5.5	23
473	Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials. <i>Parkinsonism and Related Disorders</i> , 2016 , 28, 41-48	3.6	23
472	Validation of the movement disorder society criteria for the diagnosis of 4-repeat tauopathies. <i>Movement Disorders</i> , 2020 , 35, 171-176	7	23
471	Comparison of botulinum toxin injection procedures in adductor spasmodic dysphonia. <i>The Journal of Otolaryngology</i> , 1995 , 24, 345-51		23
470	Diagnostic criteria for camptocormia in Parkinson's disease: A consensus-based proposal. <i>Parkinsonism and Related Disorders</i> , 2018 , 53, 53-57	3.6	22
469	Multiple impulse control disorders developing in Parkinson's disease after initiation of amantadine. <i>Movement Disorders</i> , 2012 , 27, 326	7	22
468	'Don't delay, start today': delaying levodopa does not delay motor complications. <i>Brain</i> , 2014 , 137, 2628-302		22
467	Safety and tolerability of pardoprinox, a new partial dopamine agonist, in a randomized, controlled study of patients with advanced Parkinson's disease. <i>European Neurology</i> , 2009 , 62, 40-8	2.1	22

466	Essential myoclonus and myoclonic dystonia. <i>Movement Disorders</i> , 1997 , 12, 127	7	22
465	Antidepressants in the treatment of psychosis with comorbid depression in Parkinson disease. <i>Clinical Neuropharmacology</i> , 2004 , 27, 90-2	1.4	22
464	What is it? Case 1, 1990: progressive unilateral rigidity, bradykinesia, tremulousness, and apraxia, leading to fixed postural deformity of the involved limb. <i>Movement Disorders</i> , 1990 , 5, 341-51	7	22
463	Dopamine agonists in the treatment of dystonia. <i>Clinical Neuropharmacology</i> , 1985 , 8, 38-57	1.4	22
462	Lymphatic vasculature in human dural superior sagittal sinus: Implications for neurodegenerative proteinopathies. <i>Neuroscience Letters</i> , 2018 , 665, 18-21	3.3	22
461	Adult motor phenotype differentiates Dravet syndrome from Lennox-Gastaut syndrome and links SCN1A to early onset parkinsonian features. <i>Epilepsia</i> , 2017 , 58, e44-e48	6.4	21
460	Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease. <i>Movement Disorders</i> , 2017 , 32, 893-903	7	21
459	Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson's disease patients treated with levodopa-carbidopa intestinal gel infusion. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 968-71	3.6	21
458	Longitudinal quantitative MRI in multiple system atrophy and progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 222-5	3.6	21
457	Fatigue in Parkinson's disease: The contribution of cerebral metabolic changes. <i>Human Brain Mapping</i> , 2017 , 38, 283-292	5.9	21
456	Development of a non-motor fluctuation assessment instrument for Parkinson disease. <i>Parkinson's Disease</i> , 2011 , 2011, 292719	2.6	21
455	Dystonia in complex regional pain syndrome type I. <i>Annals of Neurology</i> , 2010 , 67, 412-4	9.4	21
454	Microelectrode recordings define the ventral posteromedial pallidotomy target. <i>Stereotactic and Functional Neurosurgery</i> , 1998 , 71, 153-63	1.6	21
453	Motor effects of stimulating the human cerebellar thalamus. <i>Journal of Physiology</i> , 1995 , 489 (Pt 1), 287-98	3.9	21
452	Normal distribution of apolipoprotein E alleles in progressive supranuclear palsy. <i>Neurology</i> , 1996 , 46, 1156-7	6.5	21
451	Case 1, 1995: psychosis, dementia, chorea, ataxia, and supranuclear gaze dysfunction. <i>Movement Disorders</i> , 1995 , 10, 257-62	7	21
450	Alpha methylparatyrosine and tetrabenazine in movement disorders. <i>Clinical Neuropharmacology</i> , 1982 , 5, 375-87	1.4	21
449	Nonsteroidal Anti-inflammatory Use and LRRK2 Parkinson's Disease Penetrance. <i>Movement Disorders</i> , 2020 , 35, 1755-1764	7	21

448	Large-scale assessment of polyglutamine repeat expansions in Parkinson disease. <i>Neurology</i> , 2015 , 85, 1283-92	6.5	20
447	Neuropathological findings in chorea-acanthocytosis: new insights into mechanisms underlying parkinsonism and seizures. <i>Acta Neuropathologica</i> , 2014 , 127, 613-5	14.3	20
446	Reduced intracortical and interhemispheric inhibitions in corticobasal syndrome. <i>Journal of Clinical Neurophysiology</i> , 2008 , 25, 304-12	2.2	20
445	Pain in Gilles de la Tourette syndrome and related tic disorders. <i>Canadian Journal of Neurological Sciences</i> , 1989 , 16, 439-41	1	20
444	Diagnostic importance of immunological markers in lymphoma involving the central nervous system. <i>Annals of Neurology</i> , 1984 , 16, 668-72	9.4	20
443	Helicobacter pylori Eradication in Parkinson's Disease: A Randomized Placebo-Controlled Trial. <i>Movement Disorders</i> , 2020 , 35, 2250-2260	7	20
442	Deep Brain Stimulation in Rare Inherited Dystonias. <i>Brain Stimulation</i> , 2016 , 9, 905-910	5.1	20
441	Alternating Hemiplegia of Childhood as a New Presentation of Adenylate Cyclase 5-Mutation-Associated Disease: A Report of Two Cases. <i>Journal of Pediatrics</i> , 2017 , 181, 306-308.e1	3.6	19
440	Effects of rasagiline on the progression of nonmotor scores of the MDS-UPDRS. <i>Movement Disorders</i> , 2015 , 30, 589-92	7	19
439	Tongue control for swallowing in Parkinson's disease: effects of age, rate, and stimulus consistency. <i>Movement Disorders</i> , 2011 , 26, 1725-9	7	19
438	Neuroprotection in Parkinson's disease: and now for something completely different?. <i>Lancet Neurology</i> , 2006 , 5, 990-1	24.1	19
437	Cardiac valvulopathy associated with pergolide use. <i>Canadian Journal of Neurological Sciences</i> , 2006 , 33, 27-33	1	19
436	Voluntary control and a wider clinical spectrum of essential palatal tremor. <i>Movement Disorders</i> , 2004 , 19, 717-9	7	19
435	The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy.. <i>Movement Disorders</i> , 2022 ,	7	19
434	MRI signs of multiple system atrophy preceding the clinical diagnosis: the case for an imaging-supported probable MSA diagnostic category. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 443-4	5.5	18
433	Repurposing drugs to treat L-DOPA-induced dyskinesia in Parkinson's disease. <i>Neuropharmacology</i> , 2019 , 147, 11-27	5.5	18
432	ADCY5-Related Dyskinesia: Improving Clinical Detection of an Evolving Disorder. <i>Movement Disorders Clinical Practice</i> , 2019 , 6, 512-520	2.2	18
431	Implications of nocturnal symptoms towards the early diagnosis of Parkinson's disease. <i>Journal of Neural Transmission</i> , 2014 , 121 Suppl 1, S49-57	4.3	18

430	Oxidative stress alters the regulatory control of p66Shc and Akt in PINK1 deficient cells. <i>Biochemical and Biophysical Research Communications</i> , 2010 , 399, 331-5	3.4	18
429	Myoclonus in complex regional pain syndrome. <i>Movement Disorders</i> , 2009 , 24, 314-6; author reply 316	7	18
428	Antidepressants and psychosis in Parkinson disease: a case series. <i>International Journal of Geriatric Psychiatry</i> , 2007 , 22, 601-4	3.9	18
427	Childhood onset in familial prion disease with a novel mutation in the PRNP gene. <i>Archives of Neurology</i> , 2006 , 63, 1016-21		18
426	Dopamine agonists and antagonists in the treatment of idiopathic dystonia. <i>Advances in Neurology</i> , 1988 , 50, 561-70		18
425	Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive-enhancing medications. <i>Movement Disorders</i> , 2018 , 33, 1769-1776	7	18
424	Repetitive transcranial magnetic stimulation plus standardized suggestion of benefit for functional movement disorders: an open label case series. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 407-12	3.6	17
423	Association Between Social Cognition Changes and Resting State Functional Connectivity in Frontotemporal Dementia, Alzheimer's Disease, Parkinson's Disease, and Healthy Controls. <i>Frontiers in Neuroscience</i> , 2019 , 13, 1259	5.1	17
422	Neuronal intranuclear inclusion disease: two cases of dopa-responsive juvenile parkinsonism with drug-induced dyskinesia. <i>Movement Disorders</i> , 2010 , 25, 1274-9	7	17
421	Standard guidelines for publication of deep brain stimulation studies in Parkinson's disease (Guide4DBS-PD). <i>Movement Disorders</i> , 2010 , 25, 1530-7	7	17
420	Mirror movements in Parkinson's disease: effect of dopaminergic drugs. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006 , 77, 1194-5	5.5	17
419	Unique form of propriospinal myoclonus as a possible complication of an enteropathogenic toxin. <i>Movement Disorders</i> , 2003 , 18, 942-8	7	17
418	Clinical phenomenology of tic disorders selected aspects. <i>Advances in Neurology</i> , 1992 , 58, 25-32		17
417	Characterization of Movement Disorder Phenomenology in Genetically Proven, Familial Frontotemporal Lobar Degeneration: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2016 , 11, e0153852	3.7	17
416	A novel KCNA1 mutation in a family with episodic ataxia and malignant hyperthermia. <i>Neurogenetics</i> , 2016 , 17, 245-249	3	17
415	Pedunculopontine nucleus stimulation in progressive supranuclear palsy: a randomised trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017 , 88, 613-616	5.5	16
414	Neuroimaging Advances in Parkinson's Disease and Atypical Parkinsonian Syndromes. <i>Frontiers in Neurology</i> , 2020 , 11, 572976	4.1	16
413	Levodopa challenge test: indications, protocol, and guide. <i>Journal of Neurology</i> , 2021 , 268, 3135-3143	5.5	16

4 ¹²	ADCK3-related Coenzyme Q10 Deficiency: A Potentially Treatable Genetic Disease. <i>Movement Disorders Clinical Practice</i> , 2018 , 5, 635-639	2.2	16
4 ¹¹	Unfreezing of gait in patients with Parkinson's disease. <i>Lancet Neurology</i> , 2015 , 14, 675-7	24.1	16
4 ¹⁰	Thalamic neuronal and EMG activity in psychogenic dystonia compared with organic dystonia. <i>Movement Disorders</i> , 2011 , 26, 1348-52	7	16
4 ⁰⁹	Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts. <i>Movement Disorders</i> , 2011 , 26, 608-13	7	16
4 ⁰⁸	Potential placebo effect in assessing idiopathic normal pressure hydrocephalus. <i>Journal of Neurosurgery</i> , 2011 , 114, 1428-31	3.2	16
4 ⁰⁷	Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease. <i>Movement Disorders</i> , 2010 , 25, 1801-8	7	16
4 ⁰⁶	Long-term effect of unilateral pallidotomy on levodopa-induced dyskinesia. <i>Movement Disorders</i> , 2010 , 25, 1496-8	7	16
4 ⁰⁵	Pallidotomy increases cortical inhibition in Parkinson's disease. <i>Canadian Journal of Neurological Sciences</i> , 1997 , 24, 133-6	1	16
4 ⁰⁴	Impact of standard of care for psychosis in Parkinson disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008 , 79, 1413-5	5.5	16
4 ⁰³	What is it? Case 1, 1994: rapidly progressive aphasia, apraxia, dementia, myoclonus, and parkinsonism. <i>Movement Disorders</i> , 1994 , 9, 358-66	7	16
4 ⁰²	Subcognitive processing in the frontocaudate "complex loop": the role of the striatum. <i>Alzheimer Disease and Associated Disorders</i> , 1990 , 4, 150-60	2.5	16
4 ⁰¹	Coexistence of idiopathic Parkinson's disease and Creutzfeldt-Jakob disease. <i>Canadian Journal of Neurological Sciences</i> , 1985 , 12, 272-3	1	16
4 ⁰⁰	Pharmacology of cranial dystonia. <i>Neurology</i> , 1983 , 33, 1100-2	6.5	16
399	Cranial dystonia, blepharospasm and hemifacial spasm: clinical features and treatment, including the use of botulinum toxin. <i>Cmaj</i> , 1988 , 139, 837-44	3.5	16
398	Telemedicine in Movement Disorders: Leçons du COVID-19. <i>Movement Disorders</i> , 2020 , 35, 1893-1896	7	16
397	Therapeutic trial design for frontotemporal dementia and related disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019 , 90, 412-423	5.5	16
396	Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. <i>Nature Medicine</i> , 2021 , 27, 1451-1457	50.5	16
395	Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 326, 926-939	27.4	16

394	Clinical diagnostic criteria. <i>Advances in Neurology</i> , 2000 , 82, 29-34		16
393	Linaclotide and Prucalopride for Management of Constipation in Patients with Parkinsonism. <i>Movement Disorders Clinical Practice</i> , 2018 , 5, 218-220	2.2	15
392	Mutation analysis of CHCHD2 in Canadian patients with familial Parkinson's disease. <i>Neurobiology of Aging</i> , 2016 , 38, 217.e7-217.e8	5.6	15
391	Role of sepiapterin reductase gene at the PARK3 locus in Parkinson's disease. <i>Neurobiology of Aging</i> , 2011 , 32, 2108.e1-5	5.6	15
390	A new sensitive imaging biomarker for Parkinson disease?. <i>Neurology</i> , 2009 , 72, 1374-5	6.5	15
389	The psychogenic toe signs. <i>Neurology</i> , 2011 , 77, 508-9	6.5	15
388	Reversible dissociation of sensitivity to dynamic stimuli in Parkinson's disease: is magnocellular function essential to reading motion-defined letters?. <i>Vision Research</i> , 1997 , 37, 3531-4	2.1	15
387	A case of a psychogenic "jumpy stump". <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006 , 77, 1104-5	4.5	15
386	Diagnosing psychogenic movement disorders-which criteria should be used in clinical practice?. <i>Nature Clinical Practice Neurology</i> , 2007 , 3, 134-5		15
385	Management of Parkinson's disease: An evidence-based review. <i>Movement Disorders</i> , 2002 , 17, i-i	7	15
384	Amoxapine shows an antipsychotic effect but worsens motor function in patients with Parkinson's disease and psychosis. <i>Clinical Neuropharmacology</i> , 2001 , 24, 242-4	1.4	15
383	Flunarizine in essential tremor. <i>Clinical Neuropharmacology</i> , 1993 , 16, 460-3	1.4	15
382	Heart rate variability in leucine-rich repeat kinase 2-associated Parkinson's disease. <i>Movement Disorders</i> , 2017 , 32, 610-614	7	14
381	Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease. <i>Journal of Visualized Experiments</i> , 2018 ,	1.6	14
380	Neurologic diagnostic criteria for functional neurologic disorders. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2016 , 139, 193-212	3	14
379	Development and validation of a carers quality-of-life questionnaire for parkinsonism (PQoL Carers). <i>Quality of Life Research</i> , 2016 , 25, 81-8	3.7	14
378	Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy. <i>Journal of Neural Transmission</i> , 2018 , 125, 1373-1379	4.3	14
377	Designing clinical trials for dystonia. <i>Neurotherapeutics</i> , 2014 , 11, 117-27	6.4	14

376	Bilateral pallidal stimulation for sargoglycan epsilon negative myoclonus. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 915-8	3.6	14
375	Similar striatal D2/D3 dopamine receptor availability in adults with Tourette syndrome compared with healthy controls: A [(11) C]-(+)-PHNO and [(11) C]raclopride positron emission tomography imaging study. <i>Human Brain Mapping</i> , 2015 , 36, 2592-601	5.9	14
374	The pill questionnaire in a nondemented Parkinson's disease population. <i>Movement Disorders</i> , 2012 , 27, 1308-11	7	14
373	Orthostatic tremor in progressive supranuclear palsy. <i>Movement Disorders</i> , 2007 , 22, 1192-4	7	14
372	The G2019S LRRK2 mutation in Brazilian patients with Parkinson's disease: phenotype in monozygotic twins. <i>Movement Disorders</i> , 2008 , 23, 290-4	7	14
371	Idiopathic generalized myokymia (Isaacs' syndrome) with hand posturing resembling dystonia. <i>Movement Disorders</i> , 1996 , 11, 448-9	7	14
370	Gestes antagonistes in the suppression of tics: "tricks for tics". <i>Movement Disorders</i> , 1995 , 10, 226-8	7	14
369	Idiopathic Parkinson's disease: revised concepts of cognitive and affective status. <i>Canadian Journal of Neurological Sciences</i> , 1988 , 15, 106-13	1	14
368	Anticholinergic Drugs and Amantadine in the Treatment of Parkinson's Disease. <i>Handbook of Experimental Pharmacology</i> , 1989 , 307-323	3.2	14
367	Microelectrode recording-guided posteroventral pallidotomy in patients with Parkinson's disease. <i>Advances in Neurology</i> , 1997 , 74, 167-74		14
366	Can Isolated Enlarged Virchow-Robin Spaces Influence the Clinical Manifestations of Parkinson's Disease?. <i>Movement Disorders Clinical Practice</i> , 2014 , 1, 67-69	2.2	13
365	Initiating dopaminergic treatment in Parkinson's disease. <i>Lancet, The</i> , 2014 , 384, 1164-6	40	13
364	Progressive ataxia and palatal tremor: Two autopsy cases of a novel tauopathy. <i>Movement Disorders</i> , 2017 , 32, 1465-1473	7	13
363	Rapid and reliable detection of exon rearrangements in various movement disorders genes by multiplex ligation-dependent probe amplification. <i>Movement Disorders</i> , 2007 , 22, 1708-14	7	13
362	Pallidotomy for tremor. <i>Movement Disorders</i> , 1998 , 13 Suppl 3, 107-10	7	13
361	Severe evening dyskinesias in advanced Parkinson's disease: clinical description, relation to plasma levodopa, and treatment. <i>Movement Disorders</i> , 1994 , 9, 173-7	7	13
360	Lithium and parkinsonism. <i>Annals of Neurology</i> , 1984 , 15, 214	9.4	13
359	Positron tomography in dystonia. <i>Advances in Neurology</i> , 1988 , 50, 249-53		13

358	Asymmetric neuromodulation of motor circuits in Parkinson's disease: The role of subthalamic deep brain stimulation. <i>Surgical Neurology International</i> , 2017 , 8, 261	1	13
357	Hallucinations, Delusions and Impulse Control Disorders in Parkinson Disease. <i>Clinics in Geriatric Medicine</i> , 2020 , 36, 105-118	3.8	13
356	Clozapine in Parkinsonian Rest Tremor: A Review of Outcomes, Adverse Reactions, and Possible Mechanisms of Action. <i>Movement Disorders Clinical Practice</i> , 2016 , 3, 116-124	2.2	13
355	Soft signs in movement disorders: friends or foes?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019 , 90, 961-962	5.5	13
354	Neuropsychiatric expression and catatonia in 22q11.2 deletion syndrome: An overview and case series. <i>American Journal of Medical Genetics, Part A</i> , 2018 , 176, 2146-2159	2.5	13
353	Surgical treatment of dystonia. <i>Advances in Neurology</i> , 1998 , 78, 185-98		13
352	Movement disorders in non-encephalopathic Hashimoto's thyroiditis. <i>Parkinsonism and Related Disorders</i> , 2018 , 55, 141-142	3.6	12
351	Clinicopathological review of pallidonigrolusian atrophy. <i>Movement Disorders</i> , 2013 , 28, 274-81	7	12
350	Functional/psychogenic movement disorders: do we know what they are?. <i>Movement Disorders</i> , 2014 , 29, 1696-7; discussion 1699-701	7	12
349	Differentiating between visual hallucination-free dementia with Lewy bodies and corticobasal syndrome on the basis of neuropsychology and perfusion single-photon emission computed tomography. <i>Alzheimer's Research and Therapy</i> , 2014 , 6, 71	9	12
348	Wilson disease: Canadian perspectives on presentation and outcomes from an adult ambulatory setting. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2012 , 26, 333-9		12
347	Expanding the phenomenology of benign hereditary chorea: evolution from chorea to myoclonus and dystonia. <i>Movement Disorders</i> , 2011 , 26, 2296-7	7	12
346	Simultaneous repetitive movements following pallidotomy or subthalamic deep brain stimulation in patients with Parkinson's disease. <i>Experimental Brain Research</i> , 2002 , 147, 322-31	2.3	12
345	Pure cerebello-olivary degeneration of Marie, Foix, and Alajouanine presenting with progressive cerebellar ataxia, cognitive decline, and chorea. <i>Movement Disorders</i> , 2003 , 18, 1550-4	7	12
344	Atypical dopa responsive parkinsonism in a patient with megalencephaly, midbrain Lewy body disease, and some pathological features of Hallervorden-Spatz disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1996 , 61, 523-7	5.5	12
343	Neurodegenerative Diseases: Neurobiology, Pathogenesis and Therapeutics 2005 ,		12
342	Integrated Therapy for Functional Movement Disorders: Time for a Change. <i>Movement Disorders Clinical Practice</i> , 2020 , 7, 169-174	2.2	12
341	Corticobasal degeneration. <i>International Review of Neurobiology</i> , 2019 , 149, 87-136	4.4	12

340	Investigating Voice as a Biomarker for Leucine-Rich Repeat Kinase 2-Associated Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2018 , 8, 503-510	5.3	12
339	Diagnostic delay in Parkinson's disease caused by PRKN mutations. <i>Parkinsonism and Related Disorders</i> , 2019 , 63, 217-220	3.6	11
338	Hiding in Plain Sight: Functional Neurological Disorders in the News. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2019 , 31, 361-367	2.7	11
337	Paroxysmal Asymmetric Dystonic Arm Posturing-A Less Recognized but Characteristic Manifestation of ATP1A3-related disease. <i>Movement Disorders Clinical Practice</i> , 2019 , 6, 312-315	2.2	11
336	The role of mutations in COL6A3 in isolated dystonia. <i>Journal of Neurology</i> , 2016 , 263, 730-4	5.5	11
335	The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013 , 43, 151-6	5.5	11
334	A practical approach to remote longitudinal follow-up of Parkinson's disease: the FOUND study. <i>Movement Disorders</i> , 2014 , 29, 743-9	7	11
333	Extensive intracranial calcifications in a patient with a novel polymerase β 1 mutation. <i>Neurology</i> , 2013 , 81, 197-8	6.5	11
332	Drug-induced cranial myoclonus. <i>Movement Disorders</i> , 2010 , 25, 2264-5	7	11
331	GDNF in Parkinson's disease: the perils of post-hoc power. <i>Journal of Neuroscience Methods</i> , 2007 , 163, 193-6	3	11
330	Acute effect of transcutaneous electrical nerve stimulation on tremor. <i>Movement Disorders</i> , 2003 , 18, 191-4	7	11
329	Association between familial tremor and Parkinson's disease. <i>Annals of Neurology</i> , 1986 , 19, 306-7	9.4	11
328	Update on dopamine agonists in Parkinson's disease: "beyond bromocriptine". <i>Canadian Journal of Neurological Sciences</i> , 1987 , 14, 474-82	1	11
327	Whole-genome sequencing suggests mechanisms for 22q11.2 deletion-associated Parkinson's disease. <i>PLoS ONE</i> , 2017 , 12, e0173944	3.7	11
326	Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee. <i>Neurology</i> , 2021 , 97, 942-957	6.5	11
325	The Logic and Pitfalls of Parkinson's Disease as "Brain-First" Versus "Body-First" Subtypes. <i>Movement Disorders</i> , 2021 , 36, 594-598	7	11
324	Serum Inflammatory Profile for the Discrimination of Clinical Subtypes in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2018 , 9, 1123	4.1	11
323	Systematic review of movement disorders and oculomotor abnormalities in Whipple's disease. <i>Movement Disorders</i> , 2018 , 33, 1700-1711	7	11

322	Orthostatic hypotension and dementia incidence: links and implications. <i>Neuropsychiatric Disease and Treatment</i> , 2019 , 15, 2181-2194	3.1	10
321	Clustering of motor and nonmotor traits in leucine-rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study. <i>Movement Disorders</i> , 2018 , 33, 960-965	7	10
320	A case of neurosyphilis presenting with myoclonus, cerebellar ataxia, and speech disturbance. <i>Movement Disorders</i> , 2012 , 27, 794	7	10
319	Protocol of a randomised delayed-start double-blind placebo-controlled multi-centre trial for Levodopa in EARly Parkinson's disease: the LEAP-study. <i>BMC Neurology</i> , 2015 , 15, 236	3.1	10
318	A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts. <i>Movement Disorders</i> , 2009 , 24, 2370-8	7	10
317	Is there seasonal variation in risk of Parkinson's disease?. <i>Movement Disorders</i> , 2007 , 22, 1097-101	7	10
316	Reversible dopamine agonist induced anterocollis in a multiple system atrophy patient. <i>Movement Disorders</i> , 2007 , 22, 2292-3	7	10
315	Rapidly progressive sporadic dentatorubral pallidoluysian atrophy with intracytoplasmic inclusions and no CAG repeat expansion. <i>Movement Disorders</i> , 2006 , 21, 2251-4	7	10
314	Subthalamic stimulation for Parkinson's disease--living better electrically?. <i>New England Journal of Medicine</i> , 2003 , 349, 1888-91	59.2	10
313	Role of SCA2 mutations in early- and late-onset dopa-responsive parkinsonism. <i>Annals of Neurology</i> , 2002 , 52, 257-8; author reply 258	9.4	10
312	Subthalamic DBS replaces levodopa in Parkinson's disease. <i>Neurology</i> , 2002 , 59, 1293-4; author reply 1294	6.5	10
311	Tizanidine in cranial dystonia. <i>Clinical Neuropharmacology</i> , 1992 , 15, 142-7	1.4	10
310	Clinical differences between metoclopramide- and antipsychotic-induced tardive dyskinesias. <i>Canadian Journal of Neurological Sciences</i> , 1990 , 17, 137-9	1	10
309	Levodopa dose-related fluctuations in presumed olivopontocerebellar atrophy. <i>Movement Disorders</i> , 1986 , 1, 93-102	7	10
308	Decreased pallidal vesicular monoamine transporter type 2 availability in Parkinson's disease: The contribution of the nigropallidal pathway. <i>Neurobiology of Disease</i> , 2019 , 124, 176-182	7.5	10
307	Medial pallidotomy in late-stage Parkinson's disease and striatonigral degeneration. <i>Advances in Neurology</i> , 1997 , 74, 199-211		10
306	Voxel-based imaging of translocator protein 18 kDa (TSPO) in high-resolution PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013 , 33, 348-50	7.3	9
305	Comprehensive mutational analysis of LRRK2 reveals variants supporting association with autosomal dominant Parkinson's disease. <i>Journal of Human Genetics</i> , 2011 , 56, 671-5	4.3	9

304	Sporadic case of dentatorubral pallidoluysian atrophy with no CAG repeat expansion and no intranuclear inclusions. <i>Movement Disorders</i> , 2004 , 19, 580-3	7	9
303	Outcome measures for clinical trials in Parkinson's disease: achievements and shortcomings. <i>Expert Review of Neurotherapeutics</i> , 2004 , 4, 985-93	4.3	9
302	Cortical reflex myoclonus studied with cortical electrodes. <i>Clinical Neurophysiology</i> , 1999 , 110, 1521-30	4.3	9
301	Spasmodic dysphonia in Gilles de la Tourette's disease. <i>Archives of Neurology</i> , 1983 , 40, 51-2		9
300	Remoxipride in the treatment of levodopa-induced psychosis. <i>Journal of Clinical Psychopharmacology</i> , 1996 , 16, 395-9	1.7	9
299	Fosmetpantotenate Randomized Controlled Trial in Pantothenate Kinase-Associated Neurodegeneration. <i>Movement Disorders</i> , 2021 , 36, 1342-1352	7	9
298	Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease. <i>Annals of Neurology</i> , 2021 , 90, 76-88	9.4	9
297	Parkinson's Disease, NOTCH3 Genetic Variants, and White Matter Hyperintensities. <i>Movement Disorders</i> , 2020 , 35, 2090-2095	7	8
296	Genome-wide variant by serum urate interaction in Parkinson's disease. <i>Annals of Neurology</i> , 2015 , 78, 731-41	9.4	8
295	Event-related desynchronization of motor cortical oscillations in patients with multiple system atrophy. <i>Experimental Brain Research</i> , 2010 , 206, 1-13	2.3	8
294	Reply: Based on the available randomized trial patients should say no to glutathione for Parkinson's disease. <i>Movement Disorders</i> , 2010 , 25, 961-2; author reply 962-3	7	8
293	Pergolide associated cardiac valvulopathy based on Ontario administrative data. <i>Canadian Journal of Neurological Sciences</i> , 2008 , 35, 173-8	1	8
292	Insights into brain function through the examination of art: the influence of neurodegenerative diseases. <i>NeuroReport</i> , 2004 , 15, 933-7	1.7	8
291	Stiff-Person Syndrome. <i>Canadian Journal of Neurological Sciences</i> , 1992 , 19, 383-388	1	8
290	A case cluster of variant Creutzfeldt-Jakob disease linked to the Kingdom of Saudi Arabia. <i>Brain</i> , 2016 , 139, 2609-2616	11.2	8
289	Dancing Dorsal Quadrilaterals: A Novel Peripherally Induced Movement Disorder. <i>JAMA Neurology</i> , 2019 , 76, 351-354	17.2	8
288	Basal ganglia calcification in a case of PKAN. <i>Parkinsonism and Related Disorders</i> , 2017 , 36, 98-99	3.6	7
287	Increased markers of cardiac vagal activity in leucine-rich repeat kinase 2-associated Parkinson's disease. <i>Clinical Autonomic Research</i> , 2019 , 29, 603-614	4.3	7

286	Adult-onset neuronal intranuclear inclusion disease mimicking Fragile X-associated tremor-ataxia syndrome in ethnic Chinese patients. <i>Parkinsonism and Related Disorders</i> , 2020 , 74, 25-27	3.6	7
285	Oculogyric crises in PLA2G6 associated neurodegeneration. <i>Parkinsonism and Related Disorders</i> , 2018 , 52, 111-112	3.6	7
284	Actigraphy Detects Greater Intra-Individual Variability During Gait in Non-Manifesting LRRK2 Mutation Carriers. <i>Journal of Parkinson's Disease</i> , 2018 , 8, 131-139	5.3	7
283	Successful treatment of functional palatal tremor: Insights into pathogenesis and management. <i>Movement Disorders</i> , 2015 , 30, 875-6	7	7
282	Michael J. Fox Foundation LRRK2 Consortium: geographical differences in returning genetic research data to study participants. <i>Genetics in Medicine</i> , 2014 , 16, 644-5	8.1	7
281	Translational research in neurology and neuroscience 2011: movement disorders. <i>Archives of Neurology</i> , 2011 , 68, 709-16		7
280	Does severity of Parkinson's disease vary according to season?. <i>Movement Disorders</i> , 2005 , 20, 476-479	7	7
279	The classification of akathisia. <i>Movement Disorders</i> , 1995 , 10, 235-7	7	7
278	Parkinsonian Tremor. <i>Neurological Disease and Therapy</i> , 2005 , 195-220		7
277	The effects of pallidotomy on Parkinson's disease: study design and assessment techniques. <i>Acta Neurochirurgica Supplementum</i> , 1997 , 68, 24-8	1.7	7
276	Parkinsonism as a Sequela of SARS-CoV-2 Infection: Pure Hypoxic Injury or Additional COVID-19-Related Response?. <i>Movement Disorders</i> , 2021 , 36, 1483-1484	7	7
275	Posteroventral medial pallidotomy in advanced Parkinson's disease. <i>Advances in Neurology</i> , 1999 , 80, 575-83		7
274	Sleep-related motor and behavioral disorders: Recent advances and new entities. <i>Movement Disorders</i> , 2018 , 33, 1042-1055	7	6
273	Speech and Voice Disorders in Parkinson's Disease 2011 , 346-360		6
272	LRRK2 and Parkin mutations in a family with parkinsonism-Lack of genotype-phenotype correlation. <i>Neurobiology of Aging</i> , 2010 , 31, 721-2	5.6	6
271	Alien hand syndrome and dystonia in a pediatric patient. <i>Movement Disorders</i> , 2009 , 24, 1557-9	7	6
270	The grasp reflex: a symptom in need of treatment. <i>Movement Disorders</i> , 2010 , 25, 2479-85	7	6
269	Neuronal activity in the globus pallidus of multiple system atrophy patients. <i>Movement Disorders</i> , 2004 , 19, 1485-92	7	6

268	Dopa-responsive dystonia presenting with prominent isolated bilateral resting leg tremor: Evidence for a role of parkin?. <i>Movement Disorders</i> , 2003 , 18, 1070-1072	7	6
267	Drug-Induced Parkinsonism 103-139		6
266	Dopa-responsive parkinsonism with normal 6[18F]-fluorodopa positron emission tomography scans. <i>Annals of Neurology</i> , 1990 , 28, 592-3	9.4	6
265	Long latency between the onset of motor and vocal tics in Tourette's syndrome. <i>Annals of Neurology</i> , 1983 , 14, 693-4	9.4	6
264	Focal paroxysmal kinesigenic choreoathetosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1984 , 47, 1057-8	5.5	6
263	Parkinson's disease in 1984: an update. <i>Cmaj</i> , 1984 , 131, 1031-7		6
262	The Ontario Neurodegenerative Disease Research Initiative		6
261	Reply to: "A New Day: The Role of Telemedicine in Reshaping Care for Persons With Movement Disorders". <i>Movement Disorders</i> , 2020 , 35, 1903-1904	7	6
260	Beta-propeller protein associated neurodegeneration (BPAN); the first report of three patients from Iran with de novo novel mutations. <i>Parkinsonism and Related Disorders</i> , 2019 , 61, 231-233	3.6	6
259	Primary brain calcification due to a homozygous MYORG mutation causing isolated paroxysmal kinesigenic dyskinesia. <i>Brain</i> , 2020 , 143, e36	11.2	6
258	Myoclonus in parkinsonian disorders. <i>Advances in Neurology</i> , 2002 , 89, 77-83		6
257	Tremor-Dominant Pantothenate Kinase-associated Neurodegeneration. <i>Movement Disorders Clinical Practice</i> , 2017 , 4, 772-774	2.2	5
256	Placebos in clinical trials: unravelling a complex phenomenon. <i>Lancet Neurology, The</i> , 2017 , 16, 28-29	24.1	5
255	Genetic Variation in the Ontario Neurodegenerative Disease Research Initiative. <i>Canadian Journal of Neurological Sciences</i> , 2019 , 46, 491-498	1	5
254	The clinical significance of lower limb tremors. <i>Parkinsonism and Related Disorders</i> , 2019 , 65, 165-171	3.6	5
253	PET Tau Imaging and Motor Impairments Differ Between Corticobasal Syndrome and Progressive Supranuclear Palsy With and Without Alzheimer's Disease Biomarkers. <i>Frontiers in Neurology</i> , 2020 , 11, 574	4.1	5
252	Learning More from Finger Tapping in Parkinson's Disease: Up and Down from Dyskinesia to Bradykinesia. <i>Movement Disorders Clinical Practice</i> , 2016 , 3, 184-187	2.2	5
251	Tremor in Spinocerebellar Ataxia Type 12. <i>Movement Disorders Clinical Practice</i> , 2014 , 1, 76-78	2.2	5

250	Early-onset tardive dyskinesia in a neuroleptic-naive patient exposed to low-dose quetiapine. <i>Movement Disorders</i> , 2011 , 26, 2297-8	7	5
249	Rasagiline-induced spontaneous ejaculation. <i>Movement Disorders</i> , 2009 , 24, 2160-1	7	5
248	Clinical vignettes in Parkinson's disease: a collection of unusual medication-induced hallucinations, delusions, and compulsive behaviours. <i>International Journal of Neuroscience</i> , 2011 , 121, 472-6	2	5
247	Hemichorea-hemiballism associated with hyperglycemia and a developmental venous anomaly. <i>Neurology</i> , 2012 , 78, 838-9	6.5	5
246	A survey on the impact of the menstrual cycle on movement disorders severity. <i>Canadian Journal of Neurological Sciences</i> , 2010 , 37, 478-81	1	5
245	Fixed dystonia unresponsive to pallidal stimulation improved by motor cortex stimulation. <i>Neurology</i> , 2007 , 69, 1062-3; author reply 1063	6.5	5
244	. <i>Current Opinion in Neurology</i> , 2003 , 16, 523-527	7.1	5
243	Manipulating the dopaminergic system in Parkinson's disease 1987 , 32, 51-76		5
242	A Bayesian mathematical model of motor and cognitive outcomes in Parkinson's disease. <i>PLoS ONE</i> , 2017 , 12, e0178982	3.7	5
241	The retina as a window to the basal ganglia: Systematic review of the potential link between retinopathy and hyperkinetic disorders in diabetes. <i>Parkinsonism and Related Disorders</i> , 2020 , 80, 194-198 ⁶	3.6	5
240	Twinkle-associated familial parkinsonism with Lewy pathology: Cause or predisposition?. <i>Neurology</i> , 2020 , 95, 644-647	6.5	5
239	Paroxysmal Hemiballism/Hemichorea Resulting from Transient Ischemic Attacks. <i>Movement Disorders Clinical Practice</i> , 2016 , 3, 303-305	2.2	5
238	Successful pallidotomy for post-hyperglycemic hemichorea-ballism. <i>Parkinsonism and Related Disorders</i> , 2019 , 61, 228-230	3.6	5
237	Opsoclonus-myoclonus-encephalopathy induced by cefepime. <i>Journal of the Neurological Sciences</i> , 2019 , 396, 33-35	3.2	5
236	Improved Segmentation of the Intracranial and Ventricular Volumes in Populations with Cerebrovascular Lesions and Atrophy Using 3D CNNs. <i>Neuroinformatics</i> , 2021 , 19, 597-618	3.2	5
235	Parkinson's Disease and COVID-19: Do We Need to Be More Patient?. <i>Movement Disorders</i> , 2021 , 36, 277	7	5
234	Neuroleptic-Induced Tardive Dyskinesia Variants ²⁵⁷⁻²⁸⁴		5
233	The Waiting Room: neurological observations made outside the movement disorder specialist's consulting office. <i>Practical Neurology</i> , 2019 , 19, 295-301	2.4	4

232	Plasma near-infrared spectroscopy for diagnosis of idiopathic Parkinson's disease: the SPIN-PD study. <i>Biomarkers in Medicine</i> , 2015 , 9, 89-97	2.3	4
231	Movement Disorders and Renal Diseases. <i>Movement Disorders Clinical Practice</i> , 2020 , 7, 763-779	2.2	4
230	Movement Disorders Due to Selective Basal Ganglia Lesions with Uremia. <i>Canadian Journal of Neurological Sciences</i> , 2020 , 47, 350-365	1	4
229	Exacerbation of psychosis triggered by a synthetic cannabinoid in a 70-year-old woman with Parkinson disease. <i>Cmaj</i> , 2018 , 190, E50-E52	3.5	4
228	Progression of neuropsychiatric and cognitive features due to exons 2 to 5 deletion in the epsilon-sarcoglycan gene: a case report. <i>Neurocase</i> , 2016 , 22, 215-9	0.8	4
227	Pantothenate kinase-associated neurodegeneration mimicking Tourette syndrome: a case report and review of the literature. <i>Neurological Sciences</i> , 2018 , 39, 1797-1800	3.5	4
226	[F]AV-1451 binding and postmortem pathology of CBD. <i>Movement Disorders</i> , 2018 , 33, 1360-1361	7	4
225	Comment on "Is it Useful to Classify PSP and CBD as Different Disorders?". <i>Movement Disorders Clinical Practice</i> , 2018 , 5, 564-565	2.2	4
224	Deep brain stimulation in status dystonicus caused by anti-NMDA receptor encephalitis. <i>Parkinsonism and Related Disorders</i> , 2019 , 66, 255-257	3.6	4
223	Stem cell therapy for Parkinson's disease. <i>Annals of Neurology</i> , 2012 , 71, 283; author reply 284	9.4	4
222	Rapid-Onset Dystonia-Parkinsonism in a Chinese Girl with a De Novo c.2267G>A (p.R756H) Genetic Mutation. <i>Movement Disorders Clinical Practice</i> , 2015 , 2, 74-75	2.2	4
221	Reply: Parkinson's disease, DBS and suicide: a role for serotonin?. <i>Brain</i> , 2009 , 132, e127-e127	11.2	4
220	Motor and non-motor fluctuations. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2007 , 84, 157-84	3	4
219	Rapidly progressive behavioral changes and parkinsonism in a 68-year-old man. <i>Movement Disorders</i> , 2004 , 19, 534-43	7	4
218	Treatment of early Parkinson's disease. <i>Canadian Journal of Neurological Sciences</i> , 1999 , 26 Suppl 2, S39-44	4	4
217	"Weight-holding tremor": an unusual task-specific form of essential tremor?. <i>Movement Disorders</i> , 1995 , 10, 228-9	7	4
216	What is it? Case 1, 1991: a severe and fatal systemic illness first presenting with a movement disorder. <i>Movement Disorders</i> , 1991 , 6, 362-70	7	4
215	What is it? Case 1, 1987: unusual tremors, bradykinesia, and cerebral lucencies. <i>Movement Disorders</i> , 1987 , 2, 321-38	7	4

214	Video-tutorial for the Movement Disorder Society criteria for progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2020 , 78, 200-203	3.6	4
213	The Cortical Basal ganglia Functional Scale (CBFS): Development and preliminary validation. <i>Parkinsonism and Related Disorders</i> , 2020 , 79, 121-126	3.6	4
212	Proprioceptive recalibration following implicit visuomotor adaptation is preserved in Parkinson's disease. <i>Experimental Brain Research</i> , 2021 , 239, 1551-1565	2.3	4
211	Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations. <i>Parkinsonism and Related Disorders</i> , 2019 , 60, 138-145	3.6	4
210	Neurostimulation for Functional Neurological Disorder: Evaluating Longitudinal Neurophysiology. <i>Movement Disorders Clinical Practice</i> , 2018 , 5, 561-563	2.2	4
209	Update on the treatment of tics. <i>Advances in Neurology</i> , 2001 , 85, 355-62		4
208	Tracking the course of prodromal Parkinson's disease. <i>Brain</i> , 2017 , 140, 259-262	11.2	3
207	Successful spinal cord stimulation for severe medication-refractory restless legs syndrome. <i>Movement Disorders</i> , 2019 , 34, 585-586	7	3
206	The evidence for multidisciplinary care in Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2020 , 20, 539-549	4.3	3
205	Forecasts for the Attainment of Major Research Milestones in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020 , 10, 1047-1055	5.3	3
204	Mild dopa-responsive dystonia in heterozygous tyrosine hydroxylase mutation carrier: Evidence of symptomatic enzyme deficiency?. <i>Parkinsonism and Related Disorders</i> , 2020 , 71, 44-45	3.6	3
203	A 21-Year Retrospective Study of the Toronto Western Hospital Deep Brain Stimulation Cohort. <i>Movement Disorders</i> , 2018 , 33, 850-852	7	3
202	Infantile-onset hand dystonia with intellectual disability: Clues to mutations. <i>Neurology</i> , 2018 , 90, 333-335	3.5	3
201	Harnessing the power of placebos in movement disorders: Insights from Parkinson's disease in clinical research and practice. <i>Movement Disorders</i> , 2018 , 33, 1195-1203	7	3
200	Single-pulse subthalamic deep brain stimulation reduces premotor-motor facilitation in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019 , 66, 224-227	3.6	3
199	Efficacy and safety of T2000 in older patients with essential tremor. <i>Parkinsonism and Related Disorders</i> , 2013 , 19, 485-6	3.6	3
198	Recurrent Impulse Control Disorder Associated with Rasagiline Treatment of Parkinson's Disease. <i>Canadian Journal of Neurological Sciences</i> , 2017 , 44, 447-448	1	3
197	Will New Genetic Techniques Like Exome Sequencing Obviate the Need for Clinical Expertise? No. <i>Movement Disorders Clinical Practice</i> , 2017 , 4, 39-41	2.2	3

196	Acute akathisia3-19		3
195	Dystonic Pseudo Foot Drop. <i>Movement Disorders Clinical Practice</i> , 2015 , 2, 295-298	2.2	3
194	Deep brain stimulation for Parkinson disease in elderly individuals. <i>JAMA Neurology</i> , 2015 , 72, 367	17.2	3
193	Effect of movement frequency on repetitive finger movements in patients with Parkinson's disease. <i>Movement Disorders</i> , 2010 , 25, 252; author reply 253	7	3
192	Progress in clinical neurosciences: a forum on the early management of Parkinson's disease. <i>Canadian Journal of Neurological Sciences</i> , 2005 , 32, 277-86	1	3
191	Acute Drug-Induced Dystonia72-102		3
190	Essential palatal tremor. <i>Movement Disorders</i> , 2001 , 16, 1202-3	7	3
189	Evaluating dopamine transporter imaging as an enrichment biomarker in a phase 2 Parkinson's disease trial. <i>BMC Neurology</i> , 2021 , 21, 459	3.1	3
188	Mendelian Randomisation Study of Smoking, Alcohol, and Coffee Drinking in Relation to Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2021 ,	5.3	3
187	Movement Disorders: Diagnosis and Assessment 2008 , 293-325		3
186	Late-Onset Mitochondrial Membrane Protein-Associated Neurodegeneration With Extensive Brain Iron Deposition. <i>Movement Disorders Clinical Practice</i> , 2020 , 7, 120-121	2.2	3
185	Value of Clinical Signs in Identifying Patients with Scans without Evidence of Dopaminergic Deficit (SWEDD). <i>Journal of Parkinson's Disease</i> , 2020 , 10, 1561-1569	5.3	3
184	Cognitive impairment in Parkinson's disease: Associations between subjective and objective cognitive decline in a large longitudinal study. <i>Parkinsonism and Related Disorders</i> , 2020 , 80, 127-132	3.6	3
183	Spinocerebellar Ataxia 40: Another Etiology Underlying Essential Tremor Syndrome. <i>Movement Disorders Clinical Practice</i> , 2021 , 8, 944-946	2.2	3
182	Tongue Protrusion Dystonia in Pantothenate Kinase-Associated Neurodegeneration. <i>Pediatric Neurology</i> , 2020 , 103, 76-78	2.9	3
181	A Distinct EEG Marker of Celiac Disease-Related Cortical Myoclonus. <i>Movement Disorders</i> , 2021 , 36, 999-1005		3
180	Neither a Novel Tau Proteinopathy nor an Expansion of a Phenotype: Reappraising Clinicopathology-Based Nosology. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	3
179	Non-Dopaminergic Pathology of Parkinson's Disease15-31		3

178	Nomenclature of Genetic Movement Disorders: Recommendations of the International Parkinson and Movement Disorder Society Task Force - An Update.. <i>Movement Disorders</i> , 2022 , 37, 905-935	7	3
177	Isolated Abdominal Motor Seizures of Mesial Parietal Origin: Epileptic Belly Dancing?. <i>Movement Disorders Clinical Practice</i> , 2019 , 6, 396-399	2.2	2
176	Jumping to overcome freezing of gait while turning in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019 , 64, 349-351	3.6	2
175	On the long-term outcome of orthostatic tremor. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 1290-1	3.6	2
174	Age-Related Parkinsonian Signs in Microdeletion 22q11.2. <i>Movement Disorders</i> , 2020 , 35, 1239-1245	7	2
173	Mild dopa-responsive dystonia in heterozygous tyrosine hydroxylase mutation carrier: Evidence of symptomatic enzyme deficiency? Response from the authors. <i>Parkinsonism and Related Disorders</i> , 2020 , 74, 80	3.6	2
172	Brain tissue pulsatility is related to clinical features of Parkinson's disease. <i>NeuroImage: Clinical</i> , 2018 , 20, 222-227	5.3	2
171	Amantadine for Gait Dysfunction in Pantothenate Kinase-Associated Neurodegeneration. <i>Canadian Journal of Neurological Sciences</i> , 2019 , 46, 782-784	1	2
170	HemiballismHemichorea 2013 , 151-161		2
169	Is there even such a thing as "idiopathic normal pressure hydrocephalus"?. <i>Annals of Neurology</i> , 2017 , 82, 1032	9.4	2
168	Author response. <i>Neurology</i> , 2015 , 85, 742-3	6.5	2
167	Reconciling Braak's model of Parkinson's disease with a prion-like spread of alpha synuclein pathology. <i>Basal Ganglia</i> , 2012 , 2, 167-170		2
166	Pain and Paresthesia in Parkinson's Disease 2011 , 315-332		2
165	Deep brain stimulation for dystonia. <i>Movement Disorders</i> , 2011 , 26 Suppl 1, S3-4	7	2
164	Polymyoclonus, laryngospasm, and cerebellar ataxia associated with adenocarcinoma and multiple neural cation channel autoantibodies. <i>Archives of Neurology</i> , 2009 , 66, 1285-7		2
163	Effect of GPi pallidotomy on neuropsychological function in Parkinson's Disease. <i>Archives of Clinical Neuropsychology</i> , 1997 , 12, 419-419	2.7	2
162	Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study. <i>Neurology</i> , 2007 , 68, 1440; author reply 1440-1	6.5	2
161	Clinical practice regarding dopamine-agonist use and driving in Parkinson's disease. <i>Canadian Journal of Neurological Sciences</i> , 2007 , 34, 438-42	1	2

160	The Pharmacology of Typical and Atypical Antipsychotics55-71		2
159	Acute Drug-Induced Akathisia140-173		2
158	Multiple system atrophy 2005 , 623-662		2
157	Potential benefits of dopamine striatal implant. <i>Annals of Neurology</i> , 1990 , 27, 109-10	9.4	2
156	CQA 206-291 in Parkinson's disease: an acute single escalating dosage study. <i>Canadian Journal of Neurological Sciences</i> , 1990 , 17, 416-9	1	2
155	Hemiballism-hemichorea. <i>Archives of Neurology</i> , 1990 , 47, 619-20		2
154	Sudden confusion with levodopa withdrawal. <i>Movement Disorders</i> , 1987 , 2, 223	7	2
153	Insulin-induced hypoglycaemia does not abolish chorea. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1982 , 45, 936-7	5.5	2
152	Iris pigmentation in idiopathic dystonia. <i>Annals of Neurology</i> , 1982 , 12, 585-6	9.4	2
151	Deep Bayesian networks for uncertainty estimation and adversarial resistance of white matter hyperintensity segmentation.. <i>Human Brain Mapping</i> , 2022 ,	5.9	2
150	Corticobasal ganglionic degeneration and/or frontotemporal dementia?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2000 , 69, 705-705	5.5	2
149	Diagnosing functional neurological disorder: seeing the whole picture. <i>CNS Spectrums</i> , 2020 , 1-8	1.8	2
148	Interhemispheric pathways in agenesis of the corpus callosum and Parkinson's disease. <i>Brain Stimulation</i> , 2020 , 13, 360-362	5.1	2
147	MRI-visible perivascular space volumes, sleep duration and daytime dysfunction in adults with cerebrovascular disease. <i>Sleep Medicine</i> , 2021 , 83, 83-88	4.6	2
146	Antiepileptics408-429		2
145	Parkinsonism in corticobasal degeneration. <i>Advances in Neurology</i> , 2000 , 82, 83-9		2
144	Levodopa and Parkinson Disease-Myths Revisited-Reply. <i>JAMA Neurology</i> , 2017 , 74, 1270-1271	17.2	1
143	Treatment of Palatal Tremor. <i>Current Clinical Neurology</i> , 2019 , 179-183	0.1	1

142	Author response: Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. <i>Neurology</i> , 2020 , 94, 144-145	6.5	1
141	Reply letter to Jinnah "Locus pocus" and Albanese "Complex dystonia is not a category in the new 2013 consensus classification": Necessary evolution, no magic!. <i>Movement Disorders</i> , 2016 , 31, 1760-1767	7	1
140	Smoldering Multiple Myeloma Associated Leukoencephalopathy Presenting with Holmes Tremor, Ataxia, and Pyramidal Syndrome. <i>Movement Disorders Clinical Practice</i> , 2018 , 5, 433-435	2.2	1
139	Commentary. <i>Movement Disorders</i> , 2013 , 28, 1806-7	7	1
138	In pursuit of prodromal Parkinson's disease. <i>Lancet Neurology, The</i> , 2015 , 14, 27-8	24.1	1
137	Reply to: Gray et al. <i>Movement Disorders</i> , 2014 , 29, 1225-6	7	1
136	Hemichorea-hemiballism associated with hyperglycemia and a developmental venous anomaly. <i>Neurology</i> , 2013 , 81, 1181	6.5	1
135	Dopamine Dysregulation Syndrome 2011 , 202-214		1
134	Clinical Features of Dementia Associated with Parkinson's Disease and Dementia with Lewy Bodies 2011 , 134-144		1
133	Anxiety Syndromes and Panic Attacks 2011 , 193-201		1
132	Neuronal Mechanisms of REM Sleep and their Role in REM Sleep Behavior Disorder 2011 , 240-245		1
131	Measuring quality of life in progressive supranuclear palsy52-59		1
130	The Emerging Entity of Pre-Motor Parkinson's Disease 2011 , 93-104		1
129	Corticobasal degeneration syndrome with basal ganglia calcification: Fahr's disease as a corticobasal look-alike?. <i>Movement Disorders</i> , 2003 , 18, 351-352	7	1
128	Movement Disorders: an Overview3-19		1
127	Selected genetically engineered models relevant to human neurodegenerative disease 2005 , 176-195		1
126	Miscellaneous Drug-Induced Movement Disorders430-441		1
125	Structural and functional magnetic resonance imaging in neurodegenerative diseases 2005 , 253-289		1

124	69-year-old man with gait disturbance and Parkinsonism. <i>Movement Disorders</i> , 2001 , 16, 548-61	7	1
123	Neonatal ablation of the nigrostriatal dopamine pathway does not influence limb development in rats. <i>Experimental Neurology</i> , 2002 , 177, 547-56	5.7	1
122	Prevalence of focal dystonias in the western area of Tottori Prefecture in Japan. <i>Movement Disorders</i> , 1996 , 11, 342-3	7	1
121	Combining Skin α -Synuclein Real-Time Quaking-Induced Conversion and Circulating Neurofilament Light Chain to Distinguish Multiple System Atrophy and Parkinson's Disease.. <i>Movement Disorders</i> , 2022 ,	7	1
120	Visual QC Protocol for FreeSurfer Cortical Parcellations from Anatomical MRI		1
119	Gait, Postural Instability, and Freezing261-373		1
118	Neuropathologic Involvement of the Dopaminergic Neuronal Systems in Parkinson's Disease7-14		1
117	Recurrent neurologic symptoms complicating venom immunotherapy in a patient with systemic mastocytosis and severe Hymenoptera allergy. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020 , 8, 780-782	5.4	1
116	Reply to: "The Logic and Pitfalls of Parkinson's as Brain- Versus Body-First Subtypes". <i>Movement Disorders</i> , 2021 , 36, 786-787	7	1
115	Dream Enactment Behavior Disorder Associated with Pallido-Nigro-Luysian Degeneration and Tau Proteinopathy. <i>Movement Disorders Clinical Practice</i> , 2021 , 8, 594-599	2.2	1
114	Expectations of Benefit in a Trial of a Candidate Disease-Modifying Treatment for Parkinson Disease. <i>Movement Disorders</i> , 2021 , 36, 1964-1967	7	1
113	A Novel COVID Era-Related Oromandibular Dyskinesia: Surgical Mask-Induced Dyskinesia?. <i>Canadian Journal of Neurological Sciences</i> , 2021 , 1-2	1	1
112	Exposure to Phosphoglycerate Kinase 1 Activators and Incidence of Parkinson's Disease. <i>Movement Disorders</i> , 2021 , 36, 2419-2425	7	1
111	Focal Predominant Forms of Posthypoxic Action Myoclonus. <i>Movement Disorders Clinical Practice</i> , 2016 , 3, 417-420	2.2	1
110	Early Clinical Predictors of Treatment-Resistant and Functional Outcomes in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2016 , 3, 53-58	2.2	1
109	Comparison of Patient and Expert Perceptions of the Attainment of Research Milestones in Parkinson's Disease. <i>Movement Disorders</i> , 2021 , 36, 171-177	7	1
108	DYT-TUBB4A (DYT4 Dystonia): New Clinical and Genetic Observations. <i>Neurology</i> , 2021 , 96, e1887-e1897.5	7.5	1
107	Suggestibility as a valuable criterion for laboratory-supported definite functional movement disorders. <i>Clinical Neurophysiology Practice</i> , 2021 , 6, 103-108	3.8	1

106	Bilingualism in Parkinson's disease: Relationship to cognition and quality of life. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2021 , 43, 199-212	2.1	1
105	Neuropsychiatric disorders and COVID-19. <i>Lancet Psychiatry</i> , 2021 , 8, 564-565	23.3	1
104	The Discovery of α -Synuclein in Lewy Pathology of Parkinson's Disease: The Inspiration of a Revolution. <i>Movement Disorders Clinical Practice</i> , 2021 , 8, 1189-1193	2.2	1
103	Contribution of rare variant associations to neurodegenerative disease presentation. <i>Npj Genomic Medicine</i> , 2021 , 6, 80	6.2	1
102	Association of apolipoprotein E variation with cognitive impairment across multiple neurodegenerative diagnoses. <i>Neurobiology of Aging</i> , 2021 , 105, 378.e1-378.e9	5.6	1
101	Commentary: Is Tardive Dyskinesia Disappearing?302-310		1
100	Dyskinesia Induced by Levodopa and Dopamine Agonists in Patients with Parkinson's Disease313-350		1
99	Rating Scales for Movement Disorders20-29		1
98	The Dopaminergic and Non-Dopaminergic Features of Parkinson's Disease1-6		1
97	Effects of Exercise on Basal Ganglia Function in Parkinson's Disease and Its Animal Models416-431		1
96	Patterns of Mixed Pathologies in Down Syndrome.. <i>Journal of Alzheimer's Disease</i> , 2022 ,	4.3	1
95	Cortical GABAergic dysfunction underlying abnormal hand movements in ARX mutation. <i>Clinical Neurophysiology</i> , 2019 , 130, 1750-1751	4.3	0
94	Diffuse Brain Calcification, a Novel SLC20A2 Variant, Vertical Supranuclear Gaze Palsy, and Systemic Lupus Erythematosus. <i>Movement Disorders Clinical Practice</i> , 2019 , 6, 403-405	2.2	0
93	CLIPPERS: A Treatable Cause of Spastic Ataxia. <i>Movement Disorders Clinical Practice</i> , 2018 , 5, 212-214	2.2	0
92	Reply: dystonia after severe head injuries. <i>Movement Disorders</i> , 2014 , 29, 578-9	7	0
91	Extreme task specificity: is it dystonia or another form of motor programming abnormality?. <i>Movement Disorders</i> , 2012 , 27, 1202-3	7	0
90	Neuroimaging Pearls from the MDS Congress Video Challenge. Part 1: Genetic Disorders.. <i>Movement Disorders Clinical Practice</i> , 2022 , 9, 297-310	2.2	0
89	Neuroimaging Pearls from the MDS Congress Video Challenge. Part 2: Acquired Disorders.. <i>Movement Disorders Clinical Practice</i> , 2022 , 9, 311-325	2.2	0

88	The second family affected with a PRDM8-related disease.. <i>Neurological Sciences</i> , 2022 , 1	3.5	○
87	Longitudinal evaluations of somatosensory-motor inhibition in Dopa-responsive dystonia.. <i>Parkinsonism and Related Disorders</i> , 2022 , 95, 40-46	3.6	○
86	Bladder Dysfunction in Parkinson's Disease and Other Parkinsonism274-283		○
85	Call the Plumber: Impaired Meningeal Lymphatic Drainage in Parkinson's Disease. <i>Movement Disorders</i> , 2021 , 36, 1125	7	○
84	Exacerbation of Stiff Person Syndrome by Selective Serotonin Reuptake Inhibitors. <i>Movement Disorders Clinical Practice</i> , 2021 , 8, 772-774	2.2	○
83	Preferences for Communication About End-of-Life Care in Atypical Parkinsonism. <i>Movement Disorders</i> , 2021 , 36, 2116-2125	7	○
82	Periodic Alternating Gaze Deviation Due to Paraneoplastic Cerebellar Degeneration. <i>Movement Disorders Clinical Practice</i> , 2021 , 8, 791-793	2.2	○
81	Multimodal Longitudinal Neurophysiological Investigations in Dopa-Responsive Dystonia. <i>Movement Disorders</i> , 2021 , 36, 1986-1987	7	○
80	Movement Disorders Associated with Hypogonadism. <i>Movement Disorders Clinical Practice</i> , 2021 , 8, 997-1011	10.11	○
79	Botulinum Toxin-Associated Prolonged Remission of Idiopathic Cervical Dystonia. <i>Canadian Journal of Neurological Sciences</i> , 2021 , 1-5	1	○
78	Is clinical assessment enough? Moving towards early differentiation of neurodegenerative parkinsonisms. <i>Brain</i> , 2021 , 144, 1040-1042	11.2	○
77	Short-term deceleration capacity of heart rate: a sensitive marker of cardiac autonomic dysfunction in idiopathic Parkinson's disease. <i>Clinical Autonomic Research</i> , 2021 , 31, 729-736	4.3	○
76	Irreversible extreme freezing of gait after dopamine agonist withdrawal. <i>Clinical Case Reports (discontinued)</i> , 2021 , 9, e04712	0.7	○
75	Case of a Man with Hemichorea and Behavioral Changes: "A Red Herring".. <i>Movement Disorders Clinical Practice</i> , 2022 , 9, 501-507	2.2	○
74	Spastic Paraplegia Type 7 and Movement Disorders: Beyond the Spastic Paraplegia.. <i>Movement Disorders Clinical Practice</i> , 2022 , 9, 522-529	2.2	○
73	Reply to "Studying reproducibility of data-driven Parkinson's disease subtypes". <i>Parkinsonism and Related Disorders</i> , 2019 , 66, 245-246	3.6	
72	Gelastic Cataplexy in Niemann Pick Type C. <i>Movement Disorders Clinical Practice</i> , 2019 , 6, 498-499	2.2	
71	Tremor with congenital mirror movements: evidence of involvement of the primary motor cortex in tremor. <i>European Journal of Neurology</i> , 2019 , 26, e66-e67	6	

- 70 Restless genital syndrome--in reply. *JAMA Neurology*, **2015**, 72, 479-80 17.2
- 69 Lessons learned: neuroprotective trials in Parkinson's disease 265-279
- 68 Abnormal brain structure mediates the association between ApoE4 and slow gait among patients with pathological cognitive impairment: Results from the Ontario Neurodegenerative Research Initiative. *Alzheimer's and Dementia*, **2020**, 16, e044540 1.2
- 67 Phenotype differences between corticobasal syndrome and progressive supranuclear palsy with and without Alzheimer's disease biomarkers. *Alzheimer's and Dementia*, **2020**, 16, e046071 1.2
- 66 The Clinical Spectrum of Functional/Psychogenic Dystonia 217-223
- 65 Dancing Dorsal Quadrilaterals-Organic or Functional?-Reply. *JAMA Neurology*, **2019**, 76, 985-986 17.2
- 64 Reply to Drs. Kurlan, Fasano, and Evans: A clinically useful definition of stereotypies. *Movement Disorders*, **2013**, 28, 405-6 7
- 63 Reply to letter: Multiple system atrophy-parkinsonism with slow progression and prolonged survival: a diagnostic catch. *Movement Disorders*, **2013**, 28, 408 7
- 62 Non-Dopaminergic Approaches to the Treatment of Parkinson's Disease **2011**, 432-454
- 61 Overview of the Medical Treatment of the Non-Motor and Non-Dopaminergic Features of Parkinson's Disease **2011**, 394-408
- 60 Sleep Disorders in Parkinson's Disease **2011**, 233-239
- 59 Psychosis in Parkinson's Disease **2011**, 170-182
- 58 Depression in Parkinson's Disease **2011**, 183-192
- 57 Neurobiology of Impulse Control Disorders in Parkinson's Disease **2011**, 215-232
- 56 Orthopedic Complications of Parkinson's Disease **2011**, 374-386
- 55 Functional Imaging Studies in Parkinson's Disease: The Non-Dopaminergic Systems **2011**, 105-110
- 54 Other Non-Motor Symptoms of Parkinson's Disease **2011**, 387-393
- 53 Therapy of the Motor Features of Parkinson's Disease. *Blue Books of Neurology*, **2010**, 34, 252-272

- 52 Treatment of Motor Complications in Advanced Parkinson's Disease **2008**, 71-90
- 51 PATIENT MANAGEMENT PROBLEM. *CONTINUUM Lifelong Learning in Neurology*, **2008**, 14, 182-193 3
- 50 Reply: The variability of levodopa response in Parkinson's disease: Is sensitization reversible?. *Movement Disorders*, **2008**, 23, 925-925 7
- 49 An update on movement disorders: exciting developments but new obstacles. *Current Opinion in Neurology*, **2007**, 20, 432-433 7.1
- 48 Normalization of voice in spasmodic dysphonia during transient global amnesia. *Movement Disorders*, **2005**, 20, 1228-9 7
- 47 Corticobasal degeneration **2005**, 682-696
- 46 Neurophysiology of Parkinson's disease, levodopa-induced dyskinesias, dystonia, Huntington's disease and myoclonus **2005**, 227-250
- 45 Current and potential treatments of Parkinson's disease **2005**, 612-622
- 44 Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review. *Neurology*, **2002**, 59, 1292; author reply 1292 6.5
- 43 A Major Locus for Myoclonus-Dystonia Maps to Chromosome 7q in Eight Families*. *American Journal of Human Genetics*, **2000**, 67, 1314-1319 11
- 42 What is it? Case 1, 1992: progressive gait deterioration, peripheral neuropathy, optic atrophy, bradykinesia, and dystonia in a young girl. *Movement Disorders*, **1992**, 7, 373-9 7
- 41 Common Data Elements to Facilitate Sharing and Re-use of Participant-Level Data: Assessment of Psychiatric Comorbidity Across Brain Disorders.. *Frontiers in Psychiatry*, **2022**, 13, 816465 5
- 40 Contemporary assessment and pharmacotherapy of Tourette syndrome. *Neurotherapeutics*, **2006**, 3, 192-206 6.4
- 39 Differences in Drug Pharmacokinetics and Motor Fluctuation in DYT-. *Canadian Journal of Neurological Sciences*, **2021**, 48, 734-736 1
- 38 Identical twins with progressive kyphoscoliosis and ophthalmoplegia. *Parkinsonism and Related Disorders*, **2021**, 92, 119-122 3.6
- 37 Pathophysiology of the Internal Segment of the Globus Pallidus in Parkinson's Disease. *Advances in Behavioral Biology*, **2002**, 15-21
- 36 Sleepiness and Sleep Attacks in Parkinson's Disease. *Advances in Behavioral Biology*, **2002**, 385-390
- 35 Acute Effects of Levodopa and Pallidotomy on Bimanual Repetitive Arm Movements in Patients with Parkinson's Disease. *Advances in Behavioral Biology*, **2002**, 43-50

- 34 Psychogenic Dystonia. *Medical Psychiatry*, **2006**, 277-288
- 33 Isolated Ear Clicks with Partial Voluntary Control. *Tremor and Other Hyperkinetic Movements*, **2020**, 10, 55 2
- 32 Surgery for Movement Disorders: An Overview **2009**, 1443-1466
- 31 REM Sleep Behavior Disorder and Neurodegenerative Disorders 246-256
- 30 Restless Legs Syndrome and Akathisia in Parkinson's Disease 333-345
- 29 Assessment of Non-Motor Features of Parkinson's Disease: Scales and Rating Tools 111-125
- 28 Neuropsychologic Features of Parkinson's Dementias 145-152
- 27 Sexual Dysfunction 296-303
- 26 Anatomy and Physiology of Limbic System Dysfunction in Parkinson's Disease 70-78
- 25 Orthostatic Hypotension in Parkinson's Disease 284-295
- 24 Prospects for Neuroprotective Therapies that can Modulate Non-Dopaminergic Features in Parkinson's Disease 455-461
- 23 Surgery for Non-Dopaminergic and Non-Motor Features of Parkinson's Disease 409-415
- 22 Olfactory Dysfunction 304-314
- 21 Functional Organization of the Basal Ganglia: Dopaminergic and Non-Dopaminergic Features 56-69
- 20 Functional Anatomy of the Motor and Non-Motor Circuitry of the Basal Ganglia 32-55
- 19 Animal Models of Parkinson's Disease: The Non-Motor and Non-Dopaminergic Features 79-92
- 18 Neuropathology of Dementia in Parkinson's Disease 153-162
- 17 Gastrointestinal and Swallowing Disturbances in Parkinson's Disease 257-273

16	Clinical Trial Measures of the Non-Motor Features of Parkinson's Disease	126-133	
15	Treatment of Dementia Associated with Parkinson's Disease	163-169	
14	Parkinsonism	2012, 2326-2333	
13	Other Movement Disorders	2012, 2333-2342	
12	Psychogenic dystonia	2012, 307-319	
11	"Opening" New Insights Into LRRK2 Conformation and the Microtubule. <i>Movement Disorders</i> , 2020, 35, 2162-2163		7
10	Initiating pharmacotherapy in early Parkinson's disease. <i>Lancet Neurology, The</i> , 2020, 19, 643-644		24.1
9	Teaching Video NeuroImage: "Weighing" in on an Unusual Tremor. <i>Neurology</i> , 2021, 97, e970-e971		6.5
8	Hyperglycemic hemichorea presenting with normal MRI and striatal hyperdensity on CT. <i>Neurological Sciences</i> , 2021, 42, 4341-4343		3.5
7	Augmented Restless Legs Syndrome with Marked Hyperkinesias and Impulsive-Compulsive Behaviors. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 412-414		2.2
6	Isolated lingual myoclonus in an HIV patient. <i>Parkinsonism and Related Disorders</i> , 2019, 61, 241-244		3.6
5	Inhaled Levodopa as a Potential Treatment for Diphasic Dyskinesia. <i>Movement Disorders</i> , 2021, 36, 265-266		
4	Investigating the contribution of white matter hyperintensities and cortical thickness to empathy in neurodegenerative and cerebrovascular diseases.. <i>GeroScience</i> , 2022, 1		8.9
3	Movement Disorders and Dopaminomimetic Stimulant Drugs	351-370	
2	Spontaneous Movement Disorders in Psychiatric Patients	30-52	
1	Posteroventral medial pallidotomy in Parkinson's disease. <i>Journal of Neurology</i> , 1999, 246, s028-s041		5.5